

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2024 OF THE CONDITION AND AFFAIRS OF THE

Oxford Health Plans (NJ), Inc.

NAIC Gr	· — — —		code <u>95506</u> Employer's	ID Number <u>22-2745725</u>
Organized under the Laws of		(Prior) Jersey	_, State of Domicile or Port of E	Entry NJ
Country of Domicile		United Stat	es of America	
_icensed as business type:		Health Maintena	ance Organization	
s HMO Federally Qualified? Ye	s[]No[X]			
ncorporated/Organized	04/17/1985		Commenced Business	09/12/1985
Statutory Home Office				East Brunswick, NJ, US 08816
	(Street and N			or Town, State, Country and Zip Code)
Main Administrative Office			Orive, 5th Floor	
	Shelton, CT, US 06484	(Street ar	nd Number)	203-447-4500
	wn, State, Country and Zip			Area Code) (Telephone Number)
Mail Address	9800 Health Care Lane, MN	N006-W500	,	Minnetonka, MN, US 55343
	(Street and Number or P	.O. Box)	(City o	or Town, State, Country and Zip Code)
Primary Location of Books and F	Records	4 Research	Drive, 5th Floor	
	OL # OT 110 00404	(Street ar	nd Number)	000 447 4500
	Shelton, CT, US 06484 wn, State, Country and Zip	Code)		203-447-4500 Area Code) (Telephone Number)
, ,	,,,	•	·	
nternet Website Address		WWW.OXIO	rdhealth.com	
Statutory Statement Contact		am D Olson (Name)		952-979-6160 (Area Code) (Telephone Number)
	bill1_olson@uhc.com	,	<u>, </u>	952-931-4651
	(E-mail Address)			(FAX Number)
		OFF	ICERS	
	Samuel Thom			Marilyn Victoria Hirsch #
Secretary	Jessica Lei	gh Zuba	_ Chief Financial Officer _	Richard Michael Hersch #
			HER	
Gregory Gerald Carnevale M.I	D. #, Chief Medical Officer	Nyle Brent Cottin	igton, Vice President	Heather Anastasia Lang, Assistant Secretary
			OR TRUSTEES	
Gregory Gerald Ca Jean M Mo			gelo Cerniglia # trick O'Connor #	Samuel Thomas George
State of		State of		State of
County of		County of		County of
herein described assets were the a related exhibits, schedules and ex reporting entity as of the reporting Statement Instructions and Accou not related to accounting practices	bsolute property of the said rep planations therein contained, ar period stated above, and of its nting Practices and Procedures and procedures, according to to orresponding electronic filing	orting entity, free and clear from exed or referred to, is a full a income and deductions there manual except to the extent the best of their information, k with the NAIC, when required	om any liens or claims thereon, ex and true statement of all the assets from for the period ended, and ha at: (1) state law may differ; or, (2) nowledge and belief, respectively, that is an exact copy (except for	ntity, and that on the reporting period stated above, all of the cept as herein stated, and that this statement, together with and liabilities and of the condition and affairs of the said we been completed in accordance with the NAIC Annual) that state rules or regulations require differences in reporting . Furthermore, the scope of this attestation by the described formatting differences due to electronic filing) of the enclosed
Heather Anastasia L	J	•	nt Cottington	Samuel Thomas George
Assistant Secreta	ry	Vice I	President	President
Subscribed and sworn to before m	e this	Subscribed and sworn to	to before me this	Subscribed and sworn to before me this
day of		day of		day of
			b. If no,	filing? Yes [X] No []

Date filed......
 Number of pages attached......

ASSETS

		OLIO	Current Year		Prior Year
		1	2	3	4
		A t -	Name almost to all Alexandre	Net Admitted Assets	Net Admitted
	Destrict (Ostes LL-D)	Assets	Nonadmitted Assets	(Cols. 1 - 2) 236,434,715	Assets
	Bonds (Schedule D)	230,434,713		230,434,713	210,004,137
2.	Stocks (Schedule D):	_			
	2.1 Preferred stocks				0
	2.2 Common stocks	0	0	0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)	0	0	0	0
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)	0	0	0	0
	4.3 Properties held for sale (less \$0				
	encumbrances)	0	0	0	0
		0	0		
5.	Cash (\$(12,977), Schedule E - Part 1), cash equivalents				
	(\$91,401,828 , Schedule E - Part 2) and short-term				
	investments (\$				
6.	Contract loans, (including \$0 premium notes)			0	0
7.	Derivatives (Schedule DB)			0	0
8.	Other invested assets (Schedule BA)	0	0	0	0
9.	Receivables for securities	0	0	0	0
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0	0
11.	Aggregate write-ins for invested assets				0
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
	Title plants less \$0 charged off (for Title insurers			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
	only)	0	0	0	0
	Investment income due and accrued				
		2,000,434	0	2,000,434	1, 140, 120
15.	Premiums and considerations:	100 170	0.240	100 001	E E70
	15.1 Uncollected premiums and agents' balances in the course of collection	130, 170	9,349	120,021	5,573
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$1,584,505) and				
	contracts subject to redetermination (\$81,896,901)	78,627,105	0	78,627,105	91,931,417
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	0	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0	0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				
	Net deferred tax asset			1,891,579	
19.	Guaranty funds receivable or on deposit			, ,	
	Electronic data processing equipment and software				
20.		0	0		0
21.	Furniture and equipment, including health care delivery assets	0	0		0
	(\$				
	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$ 92,533,617) and other amounts receivable				
25.	Aggregate write-ins for other-than-invested assets	2,841,492	257	2,841,235	3,482
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	F00 407 000	7 100 070	FOF 004 000	FC0 700 007
				525,094,890	
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
28.	Total (Lines 26 and 27)	532, 197, 869	7,102,979	525,094,890	562,722,837
20.	·	302, 137,000	7,102,575	323,034,030	302,722,007
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	Miscellaneous Receivables	50	50	0	3,482
	Prepaid Expenses		207	0	0
	Taxes Receivable - State				
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	2,841,492	257	2,841,235	3,482
∠∪55.	Totalo (Entes 2001 titrough 2000 plus 2030)(Elite 20 above)	2,041,432	1 231	2,041,200	0,402

LIABILITIES, CAPITAL AND SURPLUS

	LIABILITIES, CAPI	IIAL AIID	Current Year	,	Prior Year
		1	2	3	4
		Covered	Uncovered	Total	Total
1 (Claims unpaid (less \$0 reinsurance ceded)				
	Accrued medical incentive pool and bonus amounts				
	Jnpaid claims adjustment expenses				
	Aggregate health policy reserves, including the liability of	1,020,000		1,023,000	1,010,204
٦. /	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	751 984	0	751 084	8 716 510
	Aggregate life policy reserves			,	0,710,313
	Property/casualty unearned premium reserves				0
	Aggregate health claim reserves		0		
	Premiums received in advance	·	0	·	
	General expenses due or accrued		0		
	Current federal and foreign income tax payable and interest thereon			0,702,700	
	(including \$0 on realized capital gains (losses))	0	0	0	0
	Net deferred tax liability				0
	Deded reinsurance premiums payable				0
12.	Amounts withheld or retained for the account of others	0			0
13. F	Remittances and items not allocated	905 062			
	Borrowed money (including \$0 current) and				
	interest thereon \$0 (including				
	\$0 current)	0	0	0	0
15. <i>A</i>	Amounts due to parent, subsidiaries and affiliates				
	Derivatives			0	
	Payable for securities		0		0
	Payable for securities lending				0
	Funds held under reinsurance treaties (with \$				0
19. г	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$	0	0	0	0
	Reinsurance in unauthorized and certified (\$				0
	companies	0	0	0	0
	Net adjustments in assets and liabilities due to foreign exchange rates				
	Liability for amounts held under uninsured plans	3,343,443		3,343,443	21,704,007
23. <i>A</i>	Aggregate write-ins for other liabilities (including \$	2 660	0	2 660	60 004
	Current)				
	Aggregate write-ins for special surplus funds				0
					50
	Preferred capital stock				000.075
	Gross paid in and contributed surplus				
	•				
	Aggregate write-ins for other-than-special surplus funds				0
	Jnassigned funds (surplus)	XXX	XXX	347,161,220	338,655,193
	Less treasury stock, at cost:				
3	32.10 shares common (value included in Line 26			_	
	\$	XXX	XXX	0	0
3	32.20 shares preferred (value included in Line 27				
	\$0)				
	Total capital and surplus (Lines 25 to 31 minus Line 32)				
	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	525,094,890	562,722,837
	DETAILS OF WRITE-INS				
	Unclaimed Property				
2398.	Summary of remaining write-ins for Line 23 from overflow page				0
	Totals (Lines 2301 through 2303 plus 2398)(Line 23 above)	3,668	0	3,668	69,834
2502		XXX	XXX		
2598.	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001		XXX	XXX		
3002		xxx	XXX		
3003.		xxx	xxx		
	Summary of remaining write-ins for Line 30 from overflow page				
	Fotals (Lines 3001 through 3003 plus 3098)(Line 30 above)	xxx	XXX	0	0

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN			Prior Year
		Current 1	2	3
		Uncovered	Total	Total
1. M	Member Months	XXX	1,057,073	1,094,482
2. Ne	et premium income (including \$ non-health premium income)	XXX	1,997,310,453	2,024,162,317
3. Cł	hange in unearned premium reserves and reserve for rate credits	xxx	8,885,475	8,970,837
4. Fe	ee-for-service (net of \$0 medical expenses)	XXX	0	0
	isk revenue			
	ggregate write-ins for other health care related revenues			0
	ggregate write-ins for other non-health revenues			
8. To	otal revenues (Lines 2 to 7)	XXX	2,006,195,928	2,033,133,154
	ospital and Medical:			
	ospital/medical benefits			
10. Ot	ther professional services	0	4,448,102	4,525,225
11. Oı	utside referrals	0	0	0
12. Er	mergency room and out-of-area	0	73,900,603	59,176,682
13. Pr	rescription drugs	0	108.738.594	51.735.617
	ggregate write-ins for other hospital and medical			
	centive pool, withhold adjustments and bonus amounts			
	•			
16. St	ubtotal (Lines 9 to 15)	0	1,740,226,462	1,690,594,583
1	ess:			
	et reinsurance recoveries			
18. To	otal hospital and medical (Lines 16 minus 17)	0	1,740,226,462	1,690,594,583
19. No	on-health claims (net)	0	0	0
20. CI	laims adjustment expenses, including \$46,601,571 cost containment expenses	0	58,474,161	58,327,080
	eneral administrative expenses			
	crease in reserves for life and accident and health contracts (including \$, , , ,	, ,
	increase in reserves for life and accident and nearth contracts (including \$\phi\$ increase in reserves for life only)	0	0	0
	otal underwriting deductions (Lines 18 through 22)			
	et underwriting gain or (loss) (Lines 8 minus 23)			
25. Ne	et investment income earned (Exhibit of Net Investment Income, Line 17)	0	21,220,593	17,310,268
26. Ne	et realized capital gains (losses) less capital gains tax of \$360, 122	0	1,354,746	2,674
27. Ne	et investment gains (losses) (Lines 25 plus 26)	0	22,575,339	17,312,942
	et gain or (loss) from agents' or premium balances charged off [(amount recovered		, ,	
	\$(31,196))]		(22 911)	(4.110
29. Ag	ggregate write-ins for other income or expenses	0	0	0
	et income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	VVV	104 789 995	160,849,826
	ederal and foreign income taxes incurred			34,011,249
32. Ne	et income (loss) (Lines 30 minus 31)	XXX	83, 131, 770	126,838,577
DI	ETAILS OF WRITE-INS			
0601		XXX		
0602		XXX		
0603		XXX		
0698. Sເ	ummary of remaining write-ins for Line 6 from overflow page	XXX	0	0
	otals (Lines 0601 through 0603 plus 0698)(Line 6 above)	xxx	0	0
	,			
0702				
				0
	ummary of remaining write-ins for Line 7 from overflow page			
	otals (Lines 0701 through 0703 plus 0798)(Line 7 above)	XXX		0
1403				
1498. St	ummary of remaining write-ins for Line 14 from overflow page	0	0	0
1499. To	otals (Lines 1401 through 1403 plus 1498)(Line 14 above)	0	0	0
2901				
2902				
2903				
2998. St	ummary of remaining write-ins for Line 29 from overflow page	0	0	0
	otals (Lines 2901 through 2903 plus 2998)(Line 29 above)	0	0	0

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENS	1	2
		Current Year	Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	352,544,318	227,418,300
34.	Net income or (loss) from Line 32	83,131,770	126,838,577
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	0	0
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	(135,973)	792 , 124
39.	Change in nonadmitted assets	510,230	(2,504,683
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus		0
48.	Net change in capital and surplus (Lines 34 to 47)		125 , 126 , 018
49.	Capital and surplus end of reporting period (Line 33 plus 48)	361,050,345	352,544,318
	DETAILS OF WRITE-INS		, ,
4701.	217412 G. Mai 2 mg		
4702.			
4703.			
4798.			.0
	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 through 4703 plus 4798)(Line 47 above)	U	

CASH FLOW

	CASITILOW	1	2
		Current Year	
	Cook from Operations	Current Year	Prior Year
1	Cash from Operations Premiums collected net of reinsurance	2 011 417 271	2 001 412 001
1. 2.	Net investment income		
3.	Miscellaneous income		10,330,273
	Total (Lines 1 through 3)		2,017,809,260
4.	,		
5.	Benefit and loss related payments		
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
	Federal and foreign income taxes paid (recovered) net of \$		34,139,271
	Total (Lines 5 through 9)		1,875,318,586
11.	Net cash from operations (Line 4 minus Line 10)	53,035,199	142,490,674
	Cook from Investments		
12.	Cash from Investments Proceeds from investments sold, matured or repaid:		
12.	12.1 Bonds	170 545 545	75 167 //20
	12.2 Stocks	, ,	, ,
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0
	12.7 Miscellaneous proceeds		75 107 100
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	1/9,545,545	
13.	Cost of investments acquired (long-term only):	000 750 474	07 500 600
	13.1 Bonds		
	13.2 Stocks		
	13.3 Mortgage loans		0
	13.4 Real estate		
	13.5 Other invested assets		
	13.6 Miscellaneous applications		0
	13.7 Total investments acquired (Lines 13.1 to 13.6)		97,562,628
14.	Net increase/(decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(23,213,929)	(22,395,196)
	Oach from Financian and Missellaneaus Courses		
16.	Cash from Financing and Miscellaneous Sources Cash provided (applied):		
10.	16.1 Surplus notes, capital notes	0	0
	16.2 Capital and paid in surplus, less treasury stock		0
	16.3 Borrowed funds		0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
			0
	16.5 Dividends to stockholders		0
	16.6 Other cash provided (applied)		1,197,389
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	(87,308,161)	1,197,389
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(57,486,890)	121,292,867
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	161,990,949	40,698,082
	19.2 End of year (Line 18 plus Line 19.1)	104,504,059	161,990,949

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
		1

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

_			/ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	AL I OIO	01 01		OIIO DI	LINEO							
		1	Compre (Hospital 8		4	5	6	7	8	9	10	11	12	13	14
			(Hospital a	3 Niedicai)				Federal							
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Net premium income	1,997,310,453	0	758,051	0		00	0	1,996,552,402	0	0	0	0	0	0
	Change in unearned premium reserves and reserve for rate credit		0	0	0		00	0		0	0	0	0	0	0
3.	Fee-for-service (net of \$0														
	medical expenses)	0	0	0	0		00	0	0	0	0	0	0	0	XXX
4.	Risk revenue	0	0	0	0	(00	0	0	0	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0		00	0	0	0	0	0	0	0	XXX
	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	XXX	xxx	xxx	xxx	XXX	xxx	xxx	xxx	xxx	xxx	0
7.	Total revenues (Lines 1 to 6)	2,006,195,928	0	758,051	0		0	0	2,005,437,877	0	0	0	0	0	0
8.	Hospital/medical benefits	1,543,394,964	0	920,002	0	(00	0	1,542,474,962	0	0	0	0	0	XXX
9.	Other professional services	4,448,102	0	0	0	(00	0	4,448,102	0	0	0	0	0	XXX
10.	Outside referrals	0	0	0	0		00	0	0	0	0	0	0	0	XXX
11.	Emergency room and out-of-area	73,900,603	0	0	0		00	0	73,900,603	0	0	0	0	0	XXX
12.	Prescription drugs	108,738,594	0	15,496	0		00	0	108,723,098	0	0	0	0	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0		0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	9,744,199	0	2,806	0)0	0	9,741,393	0	0	0	0	0	XXX
15.	Subtotal (Lines 8 to 14)	1,740,226,462	0	938,304	0		0	0	1,739,288,158	0	0	0	0	0	XXX
16.	Net reinsurance recoveries	0	0	0	0		00	0	0	0	0	0	0	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)	1,740,226,462	0	938,304	0		00	0	1,739,288,158	0	0	0	0	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	xxx	XXX	XXX	XXX	xxx	xxx	XXX	0
19.	Claims adjustment expenses including														
	\$ 46,601,571 cost containment expenses	58,474,161	0	22, 193	0		0 0	0	58,451,968		0	0	0	0	0
20.	General administrative expenses	125,257,838	0	47,540	0		0 0	0	125,210,298	0	0	0	0	0	0
21.	Increase in reserves for accident and health contracts	0	0	0	0		00	0	0	0	0	0	0	0	xxx
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)	1,923,958,461	0	1,008,037	0		00	0	1,922,950,424	0	0	0	0	0	0
24.	Net underwriting gain or (loss) (Line 7 minus Line 23)	82,237,467	0	(249,986)	0	1	0	0	82,487,453	0	0	0	0	0	0
	DETAILS OF WRITE-INS														2007
0501. 0502.															XXX
0502.															XXX
	Summary of remaining write-ins for Line 5 from overflow page	0	0		0	() 0	0	0	0	0	0	0	0	
0599.	Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0		0	0	0	0	0	0	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	7001
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.															XXX
1302.															XXX
1303.															XXX
	Summary of remaining write-ins for Line 13 from overflow page	0	0	0	0)	0	0	0	0	0	0	0	XXX
1399.	Totals (Lines 1301 through 1303 plus 1398) (Line 13 above)	0	0	0	0		0	0	0	0	0	0	0	0	XXX

7

m

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE Oxford Health Plans (NJ), Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PART 1 - PREMIUMS				
	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual	0	0	0	0
Comprehensive (hospital and medical) group	758,051	0	0	758,051
3. Medicare Supplement	0	0	0	0
4. Vision only	0	0	0	0
5. Dental only	0	0	0	0
6. Federal Employees Health Benefits Plan	0	0	0	0
7. Title XVIII - Medicare	1,996,552,402	0	0	1,996,552,402
8. Title XIX - Medicaid	0	0	0	0
9. Credit A&H	0	0	0	0
10. Disability Income	0	0	0	0
11. Long-Term Care	0	0	0	0
12. Other health	0	0	0	0
13. Health subtotal (Lines 1 through 12)	1,997,310,453	0	0	1,997,310,453
14. Life	0	0	0	0
15. Property/casualty	0	0	0	0
16. Totals (Lines 13 to 15)	1,997,310,453	0	0	1,997,310,453

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

				P	PART 2 - CLAIM	IS INCURRED	DURING THE Y	YEAR						
	1		ehensive & Medical)	4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
Payments during the year:					•	•								
1.1 Direct	1,741,870,166	0	598,851	0	0	0	0	1,741,271,315	C	0	0	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	C	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	C	0	0	0	0	0
1.4 Net	1,741,870,166	0	598,851	0	0	0	0	1,741,271,315	C	0	0	0	0	0
Paid medical incentive pools and bonuses	8,246,028	0	1,542	0	0	0	0	8 , 244 , 486	0	0	0	0	0	0
Claim liability December 31, current yea from Part 2A:	r		,											
3.1 Direct	129,586,145	0	347,333	0	0	0	0	129,238,812	C	· 0	0	0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	C		0	0	0	J0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	C	0	0	0	0	0
3.4 Net	129,586,145	0	347,333	0	0	0	0	129,238,812	C	0	0	0	0	0
 Claim reserve December 31, current year from Part 2D: 	200 040		4 400					200 750						
4.1 Direct	292,943	0	4, 193	0	0	0	0	288,750		0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0		0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0		0	0	0	0	0
4.4 Net	292,943	0	4 , 193	0	0	0	0	288,750	C	0	0	0	0	0
Accrued medical incentive pools and bonuses, current year	7,587,426	0	10,259	0	0	0	0	7,577,167	C	0	0	0	0	0
Net health care receivables (a)	(147,407)	0	(18, 173)	0	0	0	0	(129,234)	C	0	0	0	0	0
Amounts recoverable from reinsurers December 31, current year	0	0	0	0	0	0	0	0	C	0	0	0	0	0
Claim liability December 31, prior year from Part 2A:	144 145 000		20.040					111 000 000						
8.1 Direct	141,115,833	0	32,943	0	0	0	0	141,002,000		0	0	0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0		0	0	0	0	0
8.3 Reinsurance ceded	0	0	0	0	0	0	0	0		0	0	0	0	0
8.4 Net Claim reserve December 31, prior year	141,115,833	0	32,943	0	0	0	0	141,082,890		00	0	0	0	0
from Part 2D:	000 505	_	156	_		_	_	000 400	_		0			_
9.1 Direct	298,565	0	156	0	0	0	ļ0	298,409		0	0]0	0	J
9.2 Reinsurance assumed		0	0	0	0	0	ļ0	0		0		ļ	0	0
9.3 Reinsurance ceded	298,565	0	156	0	0	0	ļ	0		0		ļ	0	J
9.4 Net	298,565	0	156	J0	0	0	0	298,409		ļu	0	ļ	0	J0
Accrued medical incentive pools and bonuses, prior year	6,089,255	0	8,995	0	0	0	0	6,080,260	0	0	0	0	0	0
Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12. Incurred Benefits: 12.1 Direct	1,730,482,263	0	935,451	0	0	0	0	1,729,546,812	C	0		0	0	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	C	0			0	0
12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12.4 Net	1,730,482,263	0	935,451	0	0	0	0	1,729,546,812	0	0	0	0	0	0
Incurred medical incentive pools and bonuses	9,744,199	0	2,806	0	0	0	0	9,741,393	0	0	0	0	0	0
					•		•				*	•		•

⁽a) Excludes \$2,141,438 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
	Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
Reported in Process of Adjustment:						•								
1.1 Direct	66,145,509	0	203,029	0	0	0	0	65,942,480	0	0	0	0	0	
1.2 Reinsurance assumed	0	0	0		0	0	0	0	0	0	0	0	0	
1.3 Reinsurance ceded	0	0	0			0	0	0		0	0	0	0	
1.4 Net	66 , 145 , 509		203,029			0		65,942,480	0	0	0		0	
Incurred but Unreported:														
2.1 Direct	63,440,636	0	144,304	0	0	0	0	63,296,332	0	0	0	0	0	
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	
2.4 Net	63,440,636	0	144,304	0	0	0	0	63,296,332	0	0	0	0	0	
Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0 .	0	0	0	0	0	
3.4 Net		0	0	0	0	0	0	0	0	0	0	0	0	
4. TOTALS:														
4.1 Direct	129,586,145	0	347,333	0	0	0	0	129,238,812	0	0	0	0	0	
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	
4.4 Net	129.586.145	0	347.333	0	0	0	0	129,238,812	0	0	0	0	0	

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

7747 = 744 = 744	Claims Paid D	Ouring the Year	Claim Reserve a December 31 o		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	0	0	0	0	0	0
Comprehensive (hospital and medical) group		515,354	63,090	288,437	146,586	33,098
Medicare Supplement	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Dental Only	0	0	0	0	0	0
6. Federal Employees Health Benefits Plan	0	0	0	0	0	0
7. Title XVIII - Medicare		1,704,779,897	2,693,729	126,833,833	39 , 185 , 148	141,381,299
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	0	0	0	0	0	0
13. Health subtotal (Lines 1 to 12)		1,705,295,251	2,756,819	127, 122, 270	39,331,734	141,414,397
14. Health care receivables (a)	3,909,576	84,429,606	0	8,983,659	3,909,576	97,470,248
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	4,118,958	4,127,070	1,281,229	6,306,196	5,400,187	6,089,255
17. Totals (Lines 13 - 14 + 15 + 16)	36,784,297	1,624,992,715	4,038,048	124,444,807	40,822,345	50,033,404

⁽a) Excludes \$2, 141,438 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

	COSMONIA T AND TROUBLE COMPTONION OF THE PRINCIPLE AND	Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024			
1.	Prior	367	356	342	343				
2.	2020	1,457	1,817	1,817	1,817	1,817			
3.	2021	XXX	1,224	2,614	2,615	2,628			
4.	2022	XXX	XXX	1,554	1,739	1,741			
5.	2023	XXX	XXX	XXX	704	775			
6.	2024	XXX	XXX	XXX	XXX	516			

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

		Sum of Cumulative N	et Amount Paid and Clain Out	n Liability, Claim Rese standing at End of Ye	erve and Medical Incention	ve Pool and Bonuses
	Year in Which Losses Were Incurred	1 2020	2 2021	3 2022	4 2023	5 2024
1.	Prior	514	356	342	343	342
2.	2020	1,712	1,831	1,817	1,817	1,817
3.	2021	XXX	1,385	2,620	2,615	2,628
4.	2022	XXX	XXX	1,817	1,745	1,741
5.	2023	XXX	XXX	XXX	740	843
6.	2024	XXX	XXX	XXX	XXX	810

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020	7,254	1,817	81	4.5	1,898	26.2	0	0	1,898	26.2
2.	2021	1.856	2.628	85	3.2	2.713	146.2	0	0	2.713	146.2
3.	2022	2,680	1,741	55	3.2	1,796	67.0	0	0	1,796	67.0
4.	2023	1,030		17	2.2	792	76.9	68	0	860	83.5
5.	2024	758	516	18	3.5	534	70.4	294	1	829	109.4

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cumulative Net Amounts Paid							
		1	2	3	4	5			
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024			
1.	Prior	9,753	9,528	9,533	9,526	9,381			
2.	2020	750,732	760,836	760,845	760,840	760,726			
3.	2021	XXX	970,955	970,688	970,683	970,359			
4.	2022	XXX	XXX	1,230,270	1,231,129	1,230,946			
5.	2023	XXX	XXX	XXX	1,635,254	1,676,632			
6.	2024	XXX	XXX	XXX	XXX	1,708,906			

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse						
	Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024		
1. Prior	11,801	9,528	9,533	9,526	9,381		
2. 2020	804,433	763 , 157	760,845	760,840	760,726		
3. 2021	XXX	1,024,398	971,847	970,683	970,359		
4. 2022	XXX	XXX	1,296,436	1,233,794	1,230,946		
5. 2023	XXX	XXX	XXX	1,780,051	1,680,602		
6. 2024	XXX	XXX	XXX	XXX	1,842,041		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020	984,545	760,726	36,328	4.8	797,054	81.0	0	0	797,054	81.0
2.	2021	1,220,006	970,359		4.1	1,010,085	82.8	0	0	1,010,085	82.8
3.	2022	1,533,369	1,230,946	43,928	3.6	1,274,874	83.1	0	0	1,274,874	83.1
4.	2023	2,032,104	1,676,632	58,437	3.5	1,735,069	85.4	3,970	44	1,739,083	85.6
5.	2024	2,005,438	1,708,906	52,137	3.1	1,761,043	87.8	133, 135	1,481	1,895,659	94.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cur	nulative Net Amounts P	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1.	Prior	10,120	9,884	9,875	9,869	9,723
2.	2020	752, 189	762,653		762,657	762,543
3.	2021	XXX	972 , 179	973,302	973,298	972,987
4.	2022	XXX	XXX	1,231,824	1,232,868	1,232,687
5.	2023	XXX	XXX	XXX	1,635,958	1,677,407
6.	2024	XXX	XXX	XXX	XXX	1,709,422

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	Amount Paid and Claim Outs	n Liability, Claim Rese standing at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1. Prior	12,315	9,884	9,875	9,869	9,723
2. 2020	806,145	764,988	762,662	762,657	762,543
3. 2021	XXX	1,025,783	974,467	973,298	972,987
4. 2022	XXX	XXX	1,298,253	1,235,539	1,232,687
5. 2023	XXX	XXX	XXX	1,780,791	1,681,445
6. 2024	XXX	XXX	XXX	XXX	1,842,851

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020	991,799	762,543		4.8	798,952	80.6	0	0	798,952	80.6
2.	2021	1,221,862	972,987	39,811	4.1	1,012,798	82.9	0	0	1,012,798	82.9
3.	2022	1,536,049	1,232,687	43,983	3.6	1,276,670	83.1	0	0	1,276,670	83.1
4.	2023	2,033,134	1,677,407	58,454	3.5	1,735,861	85.4	4,038	44	1,739,943	85.6
5.	2024	2,006,196	1,709,422	52,155	3.1	1,761,577	87.8	133,429	1,482	1,896,488	94.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY														
		1	Compreh	nensive	4	5	6	7	8	9	10	11	12	13
			(Hospital &	Medical) 3				Federal Employees						
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
2.	Additional policy reserves (a)	0	0	0	0	0	0	0	0	0	0	0	0	0
3.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
4.	Reserve for rate credits or experience rating refunds													
	(including \$0 for investment income)	0	0	0	0	0	0	0	0	0	0	0	0	0
5.	Aggregate write-ins for other policy reserves	751,984	0	355,231	0	0	0	0	396,753	0	0	0	0	0
6.	Totals (gross)	751,984	0	355,231	0	0	0	0	396,753	0	0	0	0	0
7.		0	0	0	0	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	751,984	0	355,231	0	0	0	0	396,753	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	292,943	0	4 , 193	0	0	0	0	288,750	0	0	0	0	0
	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	292,943	0	4 , 193	0	0	0	0	288,750	0	0	0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	292,943	0	4,193	0	0	0	0	288,750	0	0	0	0	0
	DETAILS OF WRITE-INS													
	Medicare Part D Risk Adjustment Factor Payable	396,753	0	0	0	0	0	0	396,753	0	0	0	0	0
0502. 0503.	Risk Adjustments Payable	355,231	0	355,231	0	0	0	0	0	0	0	0	0	0
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	751,984	0	355,231	0	0	0	0	396,753	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

⁽a) Includes \$ ______0 premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

			SIS OF EXPENSE			
	<u> </u>	Claim Adjustme 1	nt Expenses	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)	1,279,408	346,312	2,466,872	0	4,092,592
2.	Salary, wages and other benefits					
3.	Commissions (less \$0	, ,,,,,,	, , ,	, ,		, ,
٥.	ceded plus \$ 0 assumed)	0	0	32 371 931	0	32 371 931
4.	Legal fees and expenses			494,494		
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
	Traveling expenses			800,133		
7.	- '			2,217,720		
8.	Marketing and advertising		ŕ	, ,		1
9.	Postage, express and telephone		•	1,744,443		
10.	Printing and office supplies			3,346,783		
11.	Occupancy, depreciation and amortization			897,750		, ,
12.	Equipment	209,421	56,686	403,792	0	669 , 899
13.	Cost or depreciation of EDP equipment and software	2,735,824	740,537	5,275,041	0	8,751,402
14.	Outsourced services including EDP, claims, and other services	1,999,316	564,799	2,872,543	0	5 , 436 , 658
15.	Boards, bureaus and association fees			64,947		
16.	Insurance, except on real estate			1, 151, 474		
17.	Collection and bank service charges			289,828		
18.	Group service and administration fees			872,367		•
	Reimbursements by uninsured plans			·		
19.	Reimbursements from fiscal intermediaries					
20.	Real estate expenses					
21.	•					
22.	Real estate taxes	28,765	16,007	106,721	0	151,493
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes			9,537,630		
	23.2 State premium taxes					
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes	719,127	400 , 173	2,668,028	0	3,787,328
	23.5 Other (excluding federal income and real estate taxes)			0		
24.	Investment expenses not included elsewhere	0	0	0	186,068	186,068
25.	Aggregate write-ins for expenses	5,640,181	547,803	3,987,455	0	10,175,439
26.	Total expenses incurred (Lines 1 to 25)	46,601,571	11,872,590	125,257,838	186,068	(a) 183,918,067
27.	Less expenses unpaid December 31, current year	1,216,147	309,836	6,678,085	54,678	8,258,746
28.	Add expenses unpaid December 31, prior year	1,211,732	406,552	3,499,388	89,055	5,206,727
29.	Amounts receivable relating to uninsured plans, prior year	0	0	0	0	(
30.	Amounts receivable relating to uninsured plans, current year	0	0	0	0	(
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	46,597,156	11,969,306	122,079,141	220,445	180,866,048
	DETAILS OF WRITE-INS					
2501.	Miscellaneous Expenses	5,640,181	547,803	3,987,455	0	10 , 175 , 439
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25	_				
	above) des management fees of \$100,479,514 to	5,640,181	547,803	3,987,455	0	10,175,439

14

EXHIBIT OF NET INVESTMENT INCOME

		1	2 Formed During Year
1.	U.S. government bonds	Collected During Year (a)2,768,958	3,320,296
1.1	Bonds exempt from U.S. tax	(a)0	0
1.2	Other bonds (unaffiliated)	(a)5,706,019	6,019,345
1.3	Bonds of affiliates	(a)0	, ,
2.1	Preferred stocks (unaffiliated)	· /	
2.11	Preferred stocks of affiliates	(b)0	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		0
3.	Mortgage loans	(c)0	0
4.	Real estate	(d) 0	0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)12,052,146	12,067,020
7	Derivative instruments	(f)0	0
8.	Other invested assets	0	0
9.	Aggregate write-ins for investment income	0	0
10.	Total gross investment income	20,527,124	21,406,661
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		` '
14.	Depreciation on real estate and other invested assets		
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		21,220,593
2004	DETAILS OF WRITE-INS		
0901.			
0902.			
0903.	Cumman of romaining units in a faul in 0 from quadhuu naga		0
0998. 0999.	Summary of remaining write-ins for Line 9 from overflow page	0	0
1501.	Totals (Lines 0301 tillough 0300 plus 0330) (Line 3, above)		
1501.			
1502.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15, above)		0
1000.	Totals (Elics 1991 tillough 1999 plus 1999) (Elic 19, above)		<u> </u>
(a) Inclu	ides \$	00 paid for accrued int	erest on purchases.
(b) Inclu	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$. 0 paid for accrued div	vidends on purchases.
(c) Inclu	ides \$ 0 accrual of discount less \$. 0 paid for accrued int	erest on purchases.
(d) Inclu	ides \$0 for company's occupancy of its own buildings; and excludes \$0 interest on en	cumbrances.	
(e) Incli	ides \$	95 paid for accrued int	erest on purchases
. ,	des \$		
	·		
	ides \$	ederal income taxes, att	ributable to
(h) Inclu	ides \$0 interest on surplus notes and \$		

EXHIBIT OF CAPITAL GAINS (LOSSES)

			0		Δ	5
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	961,738	0	961,738	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	753, 130	0	753, 130	0	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	0	0	0	0	0
7.	Derivative instruments		0	0	0	0
8.	Other invested assets	0	0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Total capital gains (losses)	1,714,868	0	1,714,868	0	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	DASSETS	2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets
1.	Bonds (Schedule D)	0	0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
١.	3.1 First liens	0	0	0
	3.2 Other than first liens.			
4.	Real estate (Schedule A):			
- 	4.1 Properties occupied by the company	0	0	0
Ì	4.2 Properties held for the production of income			
Ì	4.3 Properties held for sale			
		0	0	
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)	0	0	0
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	9,349	17,277	7,928
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
17	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon		0	0
	Net deferred tax asset		0	
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
	Furniture and equipment, including health care delivery assets			
21.	Net adjustment in assets and liabilities due to foreign exchange rates			
22.	Receivable from parent, subsidiaries and affiliates			
23.				
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other-than-invested assets	25/	102	(155)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0
28.	Total (Lines 26 and 27)	7,102,979	7,613,209	510,230
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Miscellaneous Receivables	50	33	(17)
2502.	Prepaid Expenses	207	69	(138)
in .				
2503.				
2503. 2598.	Summary of remaining write-ins for Line 25 from overflow page			

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			Total Members at End of			6	
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months	
Health Maintenance Organizations	97,094	91,780	88,598	84,988	84,884	1,057,073	
Provider Service Organizations	0	0	0	0	0	0	
3. Preferred Provider Organizations	0	0	0	0	0	0	
4. Point of Service	0	0	0	0	0	0	
5. Indemnity Only	0	0	0	0	0	0	
Aggregate write-ins for other lines of business	0	0	0	0	0	0	
7. Total	97,094	91,780	88,598	84,988	84,884	1,057,073	
DETAILS OF WRITE-INS							
0601.							
0602.							
0603.							
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0	

OXFORD HEALTH PLANS (NJ), INC.

NOTES TO STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

Organization and Operation

Oxford Health Plans (NJ), Inc. (the "Company"), licensed as a health maintenance organization, offers its enrollees a variety of managed care programs and products through contractual arrangements with health care providers. The Company is a wholly owned subsidiary of Oxford Health Plans, LLC. Oxford Health Plans, LLC is a wholly owned subsidiary of UnitedHealth Group Incorporated. UnitedHealth Group Incorporated is a publicly held company trading on the New York Stock Exchange.

The Company was incorporated on April 17, 1985, as a health maintenance organization and operations commenced in September 1985. The Company is licensed as a health maintenance organization in 6 states. The Company has entered into contracts with physicians, hospitals, and other health care provider organizations to deliver health care services for all enrollees.

The Company offers comprehensive commercial products to employer groups. Each contract outlines the coverage provided and renewal provisions.

The Company serves as a plan sponsor offering Medicare Plans under contracts with the Centers for Medicare and Medicaid Services.

A. Accounting Practices

The statutory basis financial statements (herein referred to as "financial statements") are presented on the basis of accounting practices prescribed or permitted by the New Jersey Department of Banking and Insurance.

The New Jersey Department of Banking and Insurance recognizes only statutory accounting practices, prescribed or permitted by the state of New Jersey, for determining and reporting the financial condition and results of operations of a health maintenance organization, for determining its solvency under New Jersey Insurance Law. The state of New Jersey prescribes the use of the National Association of Insurance Commissioners' Accounting Practices and Procedures manual in effect for the accounting periods covered in the financial statements.

No significant differences exist between the practices prescribed or permitted by the state of New Jersey and the National Association of Insurance Commissioners' Accounting Practices and Procedures manual, also known as NAIC SAP, which materially affect the statutory basis net income (loss) and capital and surplus, as illustrated in the table below:

Ne	t Income (Loss)	SSAP#	F/S Page #	F/S Line #	2024	2023
(1)	Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	xxx	\$ 83,131,770	\$ 126,838,577
(2)	State prescribed practices that are an increase/(decrease) from NAIC SAP:					
	Not Applicable				_	_
(3)	State permitted practices that are an increase/(decrease) from NAIC SAP:					
	Not Applicable				_	_
(4)	NAIC SAP (1 - 2 - 3 = 4)	XXX	XXX	XXX	\$ 83,131,770	\$ 126,838,577
Ca	pital and Surplus					
(5)	Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 361,050,345	\$ 352,544,318
(6)	State prescribed practices that are an increase/(decrease) from NAIC SAP:					
	Not Applicable				_	_
(7)	State permitted practices that are an increase/(decrease) from NAIC SAP:					
	Not Applicable				_	_
(8)	NAIC SAP (5 - 6 - 7 = 8)	XXX	XXX	XXX	\$ 361,050,345	\$ 352,544,318

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of these financial statements in conformity with the NAIC Annual Statement Instructions and the National Association of Insurance Commissioners' Accounting Practices and Procedures manual include certain amounts that are based on the Company's estimates and judgments. These estimates require the Company to apply complex assumptions and judgments, often because the Company must make estimates about the effects of matters that are inherently uncertain and will change in subsequent periods. The most significant estimates relate to hospital and medical benefits, claims unpaid, aggregate health policy reserves (including medical loss ratio rebates), aggregate health claim reserves, risk corridor, and risk adjustment estimates. The Company adjusts these estimates each period as more current information becomes available. The impact of any changes in estimates is included in the determination of net income (loss) in the period in which the estimate is adjusted.

C. Accounting Policy

Basis of Presentation — The Company prepares its financial statements on the basis of accounting practices prescribed or permitted by the New Jersey Department of Banking and Insurance. These statutory practices differ from generally accepted accounting principles in the United States of America.

The Company has deemed the following to be significant differences between statutory practices and generally accepted accounting principles:

- Certain debt investments categorized as available-for-sale or held-to-maturity under generally
 accepted accounting principles are presented at the lower of book/adjusted carrying value or fair
 value in accordance with the National Association of Insurance Commissioners' designations in
 the financial statements, whereas under generally accepted accounting principles, these
 investments are shown at fair value or book/adjusted carrying value, respectively.
- Cash, cash equivalents, and short-term investments in the financial statements represent cash balances and investments with original maturities of one year or less from the time of acquisition, whereas under generally accepted accounting principles, the corresponding caption of cash, cash equivalents, and short-term investments includes cash balances and investments that will mature in one year or less from the balance sheet date. The Company reported \$13,115,208 and \$0 short-term investments as of December 31, 2024 and 2023, respectively.
- Outstanding checks are required to be netted against cash balances in the financial statements, whereas under generally accepted accounting principles, outstanding checks are presented as other liabilities
- The statutory basis statements of cash flows reconcile the corresponding captions of cash, cash equivalents, and short-term investments, which can include restricted cash reserves, with original maturities of one year or less from the time of acquisition, whereas under generally accepted accounting principles, the statements of cash flows reconcile the corresponding captions of cash, cash equivalents, and restricted cash with maturities of three months or less. Short-term investments with a final maturity of one year or less from the balance sheet date are not included in the reconciliation of generally accepted accounting principles cash flows. In addition, there are classification differences within the presentation of the cash flow categories between generally accepted accounting principles and National Association of Insurance Commissioners' Accounting Practices and Procedures manual. The statutory basis statements of cash flows are prepared in accordance with the National Association of Insurance Commissioners' Annual Statement Instructions.
- The National Association of Insurance Commissioners' Accounting Practices and Procedures manual provides for an amount to be recorded for deferred taxes on temporary differences between the financial reporting and tax basis of assets, subject to a valuation allowance and admissibility limitations on deferred tax assets (see Note 9). In addition, under the National Association of Insurance Commissioners' Accounting Practices and Procedures manual, the net change in deferred tax assets is recorded directly to unassigned funds (surplus) in the financial statements, whereas under generally accepted accounting principles, the net change in deferred tax assets is recorded as a component of the income tax provision within the income statement and is based on the ultimate recoverability of the deferred tax assets. Based on the admissibility criteria under the National Association of Insurance Commissioners' Accounting Practices and Procedures manual, any deferred tax assets determined to be nonadmitted are charged directly to surplus and excluded from the financial statements, whereas under generally accepted accounting principles, such assets are included in the balance sheet.
- Certain assets, including certain aged premium receivables, certain health care and other
 amounts receivable, prepaid expenses, and certain amounts receivable relating to uninsured
 plans are considered nonadmitted assets under the National Association of Insurance
 Commissioners' Accounting Practices and Procedures manual and are excluded from the
 financial statements and charged directly to unassigned funds (surplus).
- Comprehensive income and its components are not separately presented in the financial statements, whereas under generally accepted accounting principles, it is a requirement to present comprehensive income and its components in the financial statements.

Accounting policy disclosures that are required by the National Association of Insurance Commissioners' Annual Statement instructions are as follows:

- (1–2) Bonds and short-term investments are stated at book/adjusted carrying value if they meet National Association of Insurance Commissioners designation of one or two and stated at the lower of book/adjusted carrying value or fair value if they meet National Association of Insurance Commissioners' designation of three or higher. The Company does not have any mandatory convertible securities or Securities Valuation Office of the National Association of Insurance Commissioners identified funds (i.e.: exchange traded funds or bond mutual funds) in its bond portfolio. Amortization of bond premium or accretion of discount is calculated using the constant yield interest method. Bonds and short-term investments are valued and reported using market prices published by the Securities Valuation Office in accordance with the National Association of Insurance Commissioners' Valuation of Securities manual prepared by the Securities Valuation Office or an external pricing service;
- (3-4) The Company holds no common or preferred stock;
- (5) The Company holds no mortgage loans on real estate;

- U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors. The Company's investment policy limits investments in nonagency residential mortgage-backed securities, including home equity and sub-prime mortgages, to 10% of total cash and invested assets. Total combined investments in mortgage-backed securities and asset-backed securities cannot exceed more than 30% of total cash and invested assets;
- (7) The Company holds no investments in subsidiaries, controlled, or affiliated entities;
- (8) The Company has no investment interests with respect to joint ventures, partnerships, or limited liability companies;
- (9) The Company holds no derivatives:
- Premium deficiency reserves (inclusive of conversion reserves) and the related expenses are recognized when it is probable that expected future health care expenses, claims adjustment expenses, direct administration costs, and an allocation of indirect administration costs under a group of existing contracts will exceed anticipated future premiums and reinsurance recoveries considered over the remaining lives of the contracts, and are recorded as aggregate health policy reserves in the financial statements. Indirect administration costs arise from activities that are not specifically identifiable to a specific group of existing contracts, and therefore, those costs are fully allocated among the various contract groupings. The allocation of indirect administration costs to each contract grouping is made proportionately to the expected margins remaining in the premiums after future health care expenses, claims adjustment expenses and direct administration costs are considered. The data and assumptions underlying such estimates and the resulting reserves are periodically updated, and any adjustments are reflected as an increase in reserves for life and accident and health contracts in the financial statements in the period in which the change in estimate is identified. The Company does anticipate investment income as a factor in the premium deficiency reserve calculation (see Note 30);
- (11) Claims adjustment expenses are those costs expected to be incurred in connection with the adjustment and recording of accident and health claims. Pursuant to the terms of the management agreement (see Note 10), the Company pays a management fee to its affiliate, United HealthCare Services, Inc., in exchange for administrative and management services. A detailed review of the administrative expenses of the Company and United HealthCare Services, Inc. is performed to determine the allocation between claims adjustment expenses and general administrative expenses to be reported in the financial statements. It is the responsibility of United HealthCare Services, Inc. to pay claims adjustment expenses in the event the Company ceases operations. The Company has recorded an estimate of unpaid claims adjustment expenses associated with incurred but unpaid claims, which is included in unpaid claims adjustment expenses in the financial statements. Management believes the amount of the liability for unpaid claims adjustment expenses as of December 31, 2024 is adequate to cover the Company's cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid claims adjustment expenses are reflected in operating results in the period in which the change in estimate is identified;
- (12) The Company does not carry any fixed assets in the financial statements;
- (13) Health care and other amounts receivable consist of pharmacy rebates receivable estimated based on the most currently available data from the Company's claims processing systems and from data provided by the Company's affiliated pharmaceutical benefit manager, OptumRx, Inc. Health care and other amounts receivable also include receivables for amounts due to the Company for claim and capitation overpayments to providers, hospitals and other health care organizations. Health care and other amounts receivable are considered nonadmitted assets under the National Association of Insurance Commissioners' Accounting Practices and Procedures manual if they do not meet admissibility requirements. Accordingly, the Company has excluded receivables that do not meet the admissibility criteria from the financial statements (see Note 28).

The Company has also deemed the following to be significant accounting policies:

ASSETS

Cash and Invested Assets

- Bonds include securities with a maturity of greater than one year at the time of purchase;
- Cash equivalents include securities that have original maturity dates of three months or less from the date of acquisition. Cash equivalents also consist of the Company's share of a qualified cash pool sponsored and administered by United HealthCare Services, Inc. The investment pool is recorded at cost or book/adjusted carrying value depending on the composition of the underlying securities. Interest income from the pool accrues daily to participating members based upon ownership percentage. Cash equivalents, excluding money-market funds, are reported at cost or book/adjusted carrying value depending on the nature of the underlying security, which approximates fair value. Money-market funds are reported at fair value or net asset value as a practical expedient;
- Realized capital gains and losses on sales of investments are calculated based upon specific identification of the investments sold. These gains and losses are reported as net realized capital gains (losses) less capital gains tax in the financial statements;

The Company continually monitors the difference between amortized cost and estimated fair value of its investments. If any of the Company's investments experience a decline in value that the Company has determined is other-than-temporary, or if the Company has determined it will sell a security that is in an impaired status, the Company will record a realized loss in net realized capital gains (losses) less capital gains tax, in the financial statements. The new cost basis is not changed for subsequent recoveries in fair value. The prospective adjustment method is utilized for loan-backed securities for periods subsequent to the loss recognition (see Note 5).

Other Assets

• Premiums and Considerations — The Company reports uncollected premium balances from its insured members, groups, and the Centers for Medicare and Medicaid Services as premiums and considerations in the financial statements. Uncollected premium balances that are over 90 days past due, with the exception of amounts due from government insured plans, are considered nonadmitted assets. In addition to those balances, current balances are also considered nonadmitted if the corresponding balance greater than 90 days past due is deemed more than inconsequential. Premiums and considerations also include amounts for commercial risk adjustment receivables as defined in Section 1343 of the Affordable Care Act, the Centers for Medicare and Medicaid Services risk corridor receivables, and the Centers for Medicare and Medicaid Services risk adjustment receivables for the Medicare Plans.

Premium adjustments for the Centers for Medicare and Medicaid Services risk corridor program are accounted for as premium adjustments subject to retrospectively rated features (see Note 24). Premium adjustments for the commercial Affordable Care Act Section 1343 risk adjustment and the Centers for Medicare and Medicaid Services risk adjustment programs are accounted for as premium adjustments subject to redetermination (see Note 24).

LIABILITIES

Claims Unpaid and Aggregate Health Claim Reserves — Claims unpaid and aggregate
health claim reserves include claims processed but not yet paid, estimates for claims received
but not yet processed, estimates for the costs of health care services enrollees have received
but for which claims have not yet been submitted, and payments and liabilities for physician,
hospital, and other medical costs disputes.

The estimates for incurred but not yet reported claims are developed using an actuarial process that is consistently applied, centrally controlled, and automated. The actuarial models consider factors such as historical submission and payment data, cost trends, customer and product mix, seasonality, utilization of health care services, contracted service rates, and other relevant factors. The Company estimates such liabilities for physician, hospital, and other medical cost disputes based upon an analysis of potential outcomes, assuming a combination of litigation and settlement strategies. These estimates may change as actuarial methods change or as underlying facts upon which estimates are based change. The Company did not change actuarial methods during 2024 and 2023. Management believes the amount of claims unpaid and aggregate health claim reserves is a best estimate of the Company's liability for unpaid claims and aggregate health claim reserves as of December 31, 2024; however, actual payments may differ from those established estimates.

The Company contracts with hospitals, physicians, and other providers of health care under capitated or discounted fee for service arrangements, including a hospital per diem to provide medical care services to enrollees. Some of these contracts are with related parties (see Note 10). Capitated providers are at risk for the cost of medical care services provided to the Company's enrollees; however, the Company is ultimately responsible for the provision of services to its enrollees should the capitated provider be unable to provide the contracted services.

Aggregate Health Policy Reserves — Aggregate health policy reserves includes commercial
risk adjustment payables as defined in Section 1343 of the Affordable Care Act, Centers for
Medicare and Medicaid Services risk corridor payables, Centers for Medicare and Medicaid
Services risk adjustment payables for the Medicare Plans, and estimated medical loss ratio
rebates payable on the Medicare Plans.

Premium adjustments for the Centers for Medicare and Medicaid Services risk corridor and estimated medical loss ratio rebates are accounted for as premium adjustments subject to retrospectively rated features (see Note 24). Premium adjustments for the commercial Affordable Care Act Section 1343 risk adjustment, Centers for Medicare and Medicaid Services risk adjustment are accounted for as premium adjustments subject to redetermination (see Note 24).

CAPITAL AND SURPLUS AND MINIMUM STATUTORY REQUIREMENTS

• Restricted Cash Reserves — The Company is in compliance with the various states regulatory deposit requirements as of December 31, 2024 and 2023, respectively, for qualification purposes as a domestic and foreign insurer. The New Jersey Administrative Code also requires the Company to maintain minimum insolvency and administrative deposits with the state of New Jersey. The Company had bonds, cash equivalents, and short-term investments which are stated at book/adjusted carrying value, fair value, or net asset value depending on the underlying security on deposit with the state of New Jersey and is in compliance with the New Jersey requirements as of December 31, 2024 and 2023, respectively. This reserve is included in bonds, cash equivalents, and short-term investments in the financial statements. Interest earned on this deposit accrues to the Company (see Note 5).

Minimum Capital and Surplus — Under the laws of the state of New Jersey, the New Jersey Department of Banking and Insurance requires the Company to maintain a minimum capital and surplus equal to the greater of the New Jersey Department of Banking and Insurance adjusted consumer price index amount of \$2,448,299; 2% of the first \$150 million of annual premium revenue and 1% of annual premium revenue over \$150 million; three months of uncovered health care expenditures; or an amount equal to the sum of 8% of the annual health care expenditures (not including those expenditures paid on a capitated basis or those on a managed hospital plan basis), plus 4% of the annual hospital expenditures paid on a managed hospital payment basis. The minimum capital and surplus requirements were \$72,987,403 and \$78,873,280, for December 31, 2024 and 2023, respectively, which were based on health care and hospital expenditures, as that produced the highest minimum requirement.

Risk-based capital is a regulatory tool for measuring the minimum amount of capital appropriate for a health maintenance organization to support its overall business operations in consideration of its size and risk profile. The New Jersey Department of Banking and Insurance requires the Company to maintain minimum capital and surplus equal to the greater of the state statute as outlined above, or the company action level as calculated by the risk based capital formula, or the level needed to avoid action pursuant to the trend test in the risk-based capital formula.

The Company is also subject to minimum capital and surplus requirements in other states where it is licensed to do business.

The Company is in compliance with the minimum required capital and surplus amounts where it is licensed to do business, as of December 31, 2024 and 2023.

STATEMENTS OF OPERATIONS

 Net Premium Income and Change in Unearned Premium Reserves and Reserve for Rate Credits — Revenues consist of net premium income that is recognized in the period in which enrollees are entitled to receive health care services.

Comprehensive commercial health plans with medical loss ratios on fully insured products, as calculated under the definitions in the Affordable Care Act and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies changes to the estimated rebates and retrospective premium adjustments as change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). In addition, pursuant to Section 1343 of the Affordable Care Act, the Company records premium adjustments for changes to the commercial risk adjustment balances which are reflected in net premium income in the financial statements (see Note 24).

Medicare Plans with medical loss ratios on fully insured products, as calculated under the definitions in the Affordable Care Act and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. In addition, the Company records premium adjustments for changes to the Centers for Medicare and Medicaid Services Medicare Plans risk corridor program. Changes to these estimates are reflected in change in unearned premium reserves and reserve for rate credits in the financial statements (see Note 24). Net premium income also includes premiums under the Medicare Plans which includes Centers for Medicare and Medicaid Services premiums, including amounts pursuant to the Centers for Medicare and Medicaid Services risk adjustment program (see Note 24), member premiums, and the Centers for Medicare and Medicaid Services low-income premium subsidy for the Company's insurance risk coverage.

Total Hospital and Medical Expenses — Total hospital and medical expenses include claims
paid, claims processed but not yet paid, estimates for claims received but not yet processed,
estimates for the costs of health care services enrollees have received but for which claims have
not yet been submitted, and payments and liabilities for physician, hospital, and other medical
costs disputes.

Total hospital and medical expenses also include amounts incurred for incentive pool, withhold adjustments, and bonus amounts that are based on the underlying contractual provisions with the respective providers. In addition, adjustments to claims unpaid estimates and aggregate health claim reserves are reflected in the period once the change in estimate is identified and included in total hospital and medical expenses in the financial statements.

General Administrative Expenses — General expenses that have been paid as of the reporting date in addition to general expenses that have been incurred but are not due until a subsequent period are reported as general administrative expenses. Pursuant to the terms of the management agreement (see Note 10), the Company pays a management fee to United HealthCare Services, Inc. in exchange for administrative and management services. State income taxes are also a component of general administrative expenses. Costs for items not included within the scope of the management agreement are directly expensed as incurred. A detailed review of the administrative expenses of the Company and United HealthCare Services, Inc. is performed to determine the allocation between claims adjustment expenses and general administrative expenses to be reported in the financial statements.

OTHER

Vulnerability Due to Certain Concentrations — The Company is subject to substantial federal
and state government regulation, including licensing and other requirements relating to the
offering of the Company's existing products in new markets and offerings of new products, both
of which may restrict the Company's ability to expand its business. The business is subject to
normal claims fluctuations and environmental issues.

The Company has no commercial customers that individually exceed 10% of total direct premiums written for the years ended December 31, 2024 and 2023, respectively. The Company's commercial business represents less than 1% of total direct premiums written as of December 31, 2024 and 2023 respectively.

The Company contracts with the Centers for Medicare and Medicaid Services to serve Medicare members across the states it is licensed in, which represents 99% of total direct premiums written as of December 31, 2024 and 2023, respectively.

Recently Issued Accounting Standards

In May 2024, the National Association of Insurance Commissioners revised Statement of Statutory Accounting Principles No. 107, *Risk-Sharing Provisions of the Affordable Care Act* to remove the federal Affordable Care Act disclosure on the transitional reinsurance program and the risk corridor program (see Note 24), effective for annual 2024. The Company chose to early adopt the revision during quarter 2 of 2024.

The Company reviewed all other recently issued guidance in 2024 and 2023 that has been adopted for 2024 or subsequent years' implementation and has determined that none of the items would have a significant impact to the financial statements.

D. Going Concern

The Company has the ability and will continue to operate for a period of time sufficient to carry out its commitments, obligations and business objectives.

2. ACCOUNTING CHANGES AND CORRECTIONS OF ERRORS

No changes in accounting principles or corrections of errors have been recorded during the years ended December 31, 2024 and 2023.

3. BUSINESS COMBINATIONS AND GOODWILL

A–E. The Company was not party to a business combination during the years ended December 31, 2024 and 2023, and does not carry goodwill in its financial statements.

4. DISCONTINUED OPERATIONS

A. Discontinued Operation Disposed of or Classified as Held for Sale

- (1–4) The Company did not have any discontinued operations disposed of or classified as held for sale during 2024 and 2023.
- B. Change in Plan of Sale of Discontinued Operation Not applicable.
- C. Nature of any Significant Continuing Involvement with Discontinued Operations after Disposal Not applicable.
- D. Equity Interest Retained in the Discontinued Operation after Disposal Not applicable.

5. INVESTMENTS

For purposes of calculating gross realized gains and losses on sales of investments, the amortized cost of each investment sold is used. The gross realized gains and losses on sales of long-term investments were \$1,716,044 and \$230, respectively, for 2024 and \$16,228 and \$13,264, respectively, for 2023. There were no gross realized gains and losses on sales of short-term investments for 2024 and 2023. The net realized gains and losses are included in net realized capital gains (losses) less taxes in the financial statements. Total proceeds on the sale of long-term investments were \$99,886,512 and \$1,941,996 in 2024 and 2023, respectively. There were no proceeds on short-term investments for 2024 and 2023.

As of December 31, 2024 and 2023, the book/adjusted carrying value, fair value, and gross unrecognized unrealized gains and losses of the Company's investments, excluding cash and cash equivalents of \$91,388,851 and \$161,990,949 respectively, are disclosed in the table below:

						2024				
	Book/Adjusted Carrying Value			Gross Unrecognized Unrealized Gains		Gross Unrecognized Unrealized Losses < 1 Year		Gross Unrecognized Unrealized Losses > 1 Year	Fair Value	
U.S. government and agency securities	\$	130,757,127	\$	149,911	\$	872,720	\$	643,462	\$ 129,390,856	
State and agency municipal securities		5,737,276		3,318		8,832		13,519	5,718,243	
City and county municipal securities		3,937,451		220		_		34,260	3,903,411	
Corporate debt securities		109,118,069		373,911	_	180,607		349,964	 108,961,409	
Total bonds and short-term investments	\$	249,549,923	\$	527,360	\$	1,062,159	\$	1,041,205	\$ 247,973,919	
						2024				
	Book/Adjusted Carrying Value			Gross Unrecognized Unrealized Gains		Gross Unrecognized Unrealized Losses < 1 Year		Gross Unrecognized Unrealized Losses > 1 Year	Fair Value	
Less than one year	\$	44,214,253	\$	35,407	\$	_	\$	84,376	\$ 44,165,284	
One to five years		174,597,025		424,695		993,059		134,019	173,894,642	
Five to ten years		11,707,841		34,498		23,036		38,974	11,680,329	
Over ten years		19,030,804	_	32,760	_	46,064	_	783,836	 18,233,664	
Total bonds and short-term investments	\$	249,549,923	\$	527,360	\$	1,062,159	\$	1,041,205	\$ 247,973,919	
						2023				
		Book/Adjusted Carrying Value		Gross Unrecognized Unrealized Gains	Gross Unrecognized Unrealized Losses < 1 Year			Gross Unrecognized Unrealized Losses > 1 Year	Fair Value	
U.S. government and agency securities	\$	73,683,833	\$	267,169	\$	137,070	\$	907,003	\$ 72,906,929	
State and agency municipal securities		4,769,786		1,073		9,075		15,076	4,746,708	
City and county municipal securities		5,592,668		_		16,240		48,823	5,527,605	
Corporate debt securities		126,607,850	_	459,027	_	68,235	_	1,697,368	 125,301,274	
Total bonds	\$	210,654,137	\$	727,269	\$	230,620	\$	2,668,270	\$ 208,482,516	

Included in U.S. government and agency securities and corporate debt securities in the tables above are mortgage-related loan-backed securities, which do not have a single maturity date. For the years to maturity table above, these securities have been presented in the maturity group based on the securities' final maturity date and at a book/adjusted carrying value of \$60,170,959 and fair value of \$59,504,945.

The following table illustrates the fair value and gross unrecognized unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous unrecognized unrealized loss position as of December 31, 2024 and 2023:

unrealized loss position as o	T Dece	ember 31,	20	24 and 20	123:		124					
		<1	Year			> 1	Year			To	tal	
		Fair Value		Gross Unrecognized Unrealized Losses		Fair Value	Gross Unrecognized Unrealized Losses			Fair Value		Gross nrecognized Unrealized Losses
U.S. government and agency securities	\$	63,643,364	\$	872,720	\$	12,760,638	\$	643,462	\$	76,404,002	\$	1,516,182
State and agency municipal securities		1,632,183		8,832		2,517,742		13,519		4,149,925		22,351
City and county municipal securities		_		_		3,623,190		34,260		3,623,190		34,260
Corporate debt securities		21,814,032		180,607		23,642,809		349,964	_	45,456,841	_	530,571
Total bonds and short-term investments	\$	87,089,579	\$	1,062,159	\$	42,544,379	\$	1,041,205	\$	129,633,958	\$	2,103,364
						20	23					
		< 1 `	Year			> 1	Year					
		Fair Value		Gross rrecognized Jnrealized Losses		Fair Value		Gross rrecognized Jnrealized Losses		Fair Value		Gross nrecognized Unrealized Losses
U.S. government and agency securities	\$	24,558,427	\$	137,070	\$	19,946,365	\$	907,003	\$	44,504,792	\$	1,044,073
State and agency municipal securities		2,592,058		9,075		2,039,360		15,076		4,631,418		24,151
City and county municipal securities		2,667,717		16,240		2,859,888		48,823		5,527,605		65,063
Corporate debt securities	_	10,114,042		68,235	_	72,970,228		1,697,368	_	83,084,270		1,765,603
Total bonds	\$	39,932,244	\$	230,620	\$	97,815,841	\$	2,668,270	\$	137,748,085	\$	2,898,890

The unrecognized unrealized losses on investments in U.S. government and agency securities, state and agency municipal securities, city and county municipal securities, and corporate debt securities at December 31, 2024 and 2023, were mainly caused by interest rate fluctuations and not by unfavorable changes in the credit ratings associated with these securities. The Company evaluates impairment at each reporting period for each of the securities whereby the fair value of the investment is less than its book/adjusted carrying value. The contractual cash flows of the U.S. government and agency securities are guaranteed either by the U.S. government or an agency of the U.S. government. It is expected that the securities would not be settled at a price less than the cost of the investment, and the Company does not intend to sell the investment until the unrealized loss is fully recovered. The Company assessed the credit quality of the state and agency municipal securities, city and county municipal securities and corporate debt securities, noting whether a significant deterioration since purchase or other factors that may indicate an other-than-temporary impairment, such as the length of time and extent to which fair value has been less than cost, the financial condition, and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company's intent to sell the investment. Additionally, the Company evaluated its intent and ability to retain loan-backed securities for a period of time sufficient to recover the amortized cost. As a result of this review, no other-than-temporary impairments were recorded by the Company as of December 31, 2024 and 2023.

A–C. The Company has no mortgage loans, real estate loans, restructured debt, or reverse mortgages. The Company also has no real estate property occupied by the Company, real estate property held for the production of income, or real estate property held for sale.

D. Loan-Backed Securities

- (1) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors.
- (2) The Company did not recognize any other-than-temporary impairments on loan-backed securities as of December 31, 2024.
- (3) The Company did not have any loan-backed securities with other-than-temporary impairments to report by CUSIP as of December 31, 2024 or 2023.
- (4) The following table illustrates the fair value, gross unrecognized unrealized losses, and length of time that the loan-backed securities have been in a continuous unrecognized unrealized loss position as of December 31, 2024 and 2023:

	2024
The aggregate amount of unrealized losses:	
1. Less than 12 months	\$ 76,344
2. 12 months or longer	807,749
The aggregate related fair value of securities with unrealized losses:	
1. Less than 12 months	13,107,009
2. 12 months or longer	11,461,939
	2023
The aggregate amount of unrealized losses:	
1. Less than 12 months	\$ 40,345
2. 12 months or longer	1,088,216
The aggregate related fair value of securities with unrealized losses:	
1. Less than 12 months	6,474,113
2. 12 months or longer	22,134,786

- (5) The Company believes that it will continue to collect timely the principal and interest due on its loan-backed securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate changes and not by unfavorable changes in the credit quality associated with these securities that impacted the assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows and the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of December 31, 2024, the unrealized loss on any security that the Company classified as available-for-sale was not material to the Company's investment portfolio. Any other securities in an unrealized loss position as of December 31, 2024, the Company considers to be temporary.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions Not applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing Not applicable.
- H. Repurchase Agreements Transactions Accounted for as a Sale Not applicable.
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale Not applicable.

- J. Real Estate Not applicable.
- K. Low-Income Housing Tax Credits Not applicable.

L. Restricted Assets —

(1) Restricted assets, including pledged securities as of December 31, 2024 and 2023, are presented below:

		1	2	3	4	5	6	7
	Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted From Current Year	Total Gross (Admitted & Nonadmitted) Restricted From Prior Year	Increase/ (Decrease) (1 Minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$ —	\$ —	\$ —	\$ —	\$ —	- %	— %
b.	Collateral held under security lending agreements	_	_	_	_	_	— %	— %
C.	Subject to repurchase agreements	_	_	_	_	_	— %	— %
d.	Subject to reverse repurchase agreements	_	_	_	_	_	— %	— %
e.	Subject to dollar repurchase agreements	_	_	_	_	_	— %	— %
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	_	— %	— %
g.	Placed under option contracts	_	_	_	_	_	— %	— %
h.	Letter stock or securities restricted as to sale— excluding FHLB capital stock	_	_	_	_	_	— %	— %
i.	FHLB capital stock	_	_	_	_	_	— %	— %
j.	On deposit with states	287,367,190	216,333,130	71,034,060	_	287,367,190	54 %	55 %
k.	On deposit with other regulatory bodies	_	_	_	_	_	- %	— %
I	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	_	— %	— %
m.	Pledged as collateral not captured in other categories	_	_	_	_	_	— %	— %
n.	Other restricted assets						— %	<u> </u>
0.	Total restricted assets	\$ 287,367,190	\$ 216,333,130	\$ 71,034,060	<u>\$</u>	\$ 287,367,190	54 %	55 %

⁽a) Column 1 divided by Asset Page, Column 1, Line 28 (b) Column 5 divided by Asset Page, Column 3, Line 28

M. Working Capital Finance Investments — Not applicable.

N. Offsetting and Netting of Assets and Liabilities

The Company does not have any offsetting or netting of assets and liabilities as it relates to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and securities lending activities.

O. 5GI Securities

The Company does not have any investments with an National Association of Insurance Commissioners' designation of 5GI as of December 31, 2024 and 2023.

P. Short Sales — Not applicable.

Q. Prepayment Penalty and Acceleration Fees

The Company does not have any prepayment penalty and acceleration fees as of December 31, 2024.

R. Reporting Entity's Share of Cash Pool by Asset Type —

The Company's investment in the qualified cash pool is reported in cash equivalents. The Company's investment in the qualified cash pool is \$53,584,561 and \$156,231,048 as of December 31, 2024 and 2023, respectively. The following table presents the percent share distribution by underlying asset type of the total qualified cash pool balance as of December 31, 2024:

Asset Type	Percent Share
(1) Cash	3%
(2) Cash Equivalents	51%
(3) Short-Term Investments	46%
(4) Total	100%

S. Aggregate Collateral Loans by Qualifying Investment Collateral — Not applicable.

^(2–4) The Company has no assets pledged as collateral not captured in other categories and no other restricted assets as of December 31, 2024 or 2023.

6. JOINT VENTURES, PARTNERSHIPS, AND LIMITED LIABILITY COMPANIES

A–B. The Company has no investments in joint ventures, partnerships, or limited liability companies that exceed 10% of admitted assets and did not recognize any impairment write-down for its investments in joint ventures, partnerships, and limited liability companies during the statement periods.

7. INVESTMENT INCOME

- **A.** The Company excludes all investment income due and accrued amounts that are over 90 days past due from the financial statements.
- B. There were no investment income amounts excluded from the financial statements.
- C. The following table illustrates the gross interest income due and accrued, nonadmitted interest income due and accrued, and admitted interest income due and accrued amounts as of December 31, 2024 and 2023:

Interest Income Due And Accrued:	2024
1. Gross	\$ 2,080,454
2. Nonadmitted	· · —
3. Admitted	2,080,454
	2023
Interest Income Due And Accrued:	2023
Interest Income Due And Accrued: 1. Gross	\$ 2023 1,143,120
	\$

- D. The Company has no aggregated deferred interest as of December 31, 2024 or 2023.
- **E.** The Company has no paid-in-kind interest as of December 31, 2024 or 2023.

8. DERIVATIVE INSTRUMENTS

A-B. The Company has no derivative instruments.

9. INCOME TAXES

The corporate alternative minimum tax is calculated as 15% of adjusted financial statement income and applies only to corporations with average annual adjusted financial statement income in excess of \$1 billion for three prior taxable years. The applicability of the corporate alternative minimum tax is determined on a tax-controlled group basis.

The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group Incorporated which constitutes a controlled group. The controlled group's expected federal income tax will exceed the corporate alternative minimum tax and therefore the Company does not expect to be subject to the minimum tax.

The controlled group has not made any material modifications to the methodology used to project the corporate alternative minimum tax.

A. Deferred Tax Asset/Liability

(1) The components of the net deferred tax asset at December 31, 2024 and 2023 are as follows:

			2	024						2023			Change						
		1		2		3		4		5		6		7		8	9		
	Ordinary Capit		Capital		(Col 1+2) Total		Ordinary		Capital	(Col 4+5) Total		(Col 1 - 4) Ordinary		(Col 2 - 5) Capital			(Col 7+8) Total		
(a) Gross deferred tax assets	\$	1,901,878	\$	_	\$	1,901,878	\$	2,048,148	\$	_	\$	2,048,148	\$	(146,270)	\$	_	\$	(146,270)	
(b) Statutory valuation allowance adjustments									_							_			
(c) Adjusted gross deferred tax assets (1a - 1b)		1,901,878		_		1,901,878		2,048,148		_		2,048,148		(146,270)		_		(146,270)	
(d) Deferred tax assets nonadmitted																			
(e) Subtotal net admitted deferred tax asset (1c - 1d)		1,901,878		_		1,901,878		2,048,148		_		2,048,148		(146,270)		_		(146,270)	
(f) Deferred tax liabilities		10,299			10			20,596				20,596	(10,297)		297)			(10,297)	
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	\$	1,891,579	\$		\$	1,891,579	\$	2,027,552	\$		\$	2,027,552	\$	(135,973)	\$		\$	(135,973)	

(2) The components of the adjusted gross deferred tax assets admissibility calculation under Statement of Statutory Accounting Principles No. 101, *Income Taxes*, are as follows:

		2024					2023			Change						
	1	2		3	4		5		6		7		8		9	
Admission Calculation Components SSAP No. 101	Ordinary	Capita	ı	(Col 1 + 2) Total	Ordinary	c	apital	((Col 4 + 5) Total		(Col 1 - 4) Ordinary		ol 2 - 5) apital	(0	Col 7 + 8) Total	
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	\$ 1,901,878	\$	_	\$ 1,901,878	\$ 2,048,148	\$	_	\$ 2,048,148		\$ (146,270)		\$	_	\$	(146,270)	
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below)	_		_	_	_		_		_		_		_		_	
Adjusted gross deferred tax assets expected to be realized following the balance sheet date	_		_	_	_		_		_		_		_		_	
Adjusted gross deferred tax assets allowed per limitation threshold	xxx	х	xx	53,873,815	xxx		xxx		52,577,515		xxx		xxx		1,296,300	
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities	_		_		_						_					
(d) Deferred tax assets admitted as the result of application of SSAP No. 101 Total (2(a) + 2(b) + 2(c))	\$ 1,901,878	\$	_	\$ 1,901,878	\$ 2,048,148	\$		\$	2,048,148	\$	(146,270)	\$		\$	(146,270)	

(3) The ratio percentage and adjusted capital and surplus used to determine the recovery period and threshold limitations for the admissibility calculation are presented below:

	2024	2023
(a) Ratio percentage used to determine recovery period and threshold limitation amount	>300%	>300%
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2(b)(2) above	\$ 359,158,766	\$ 350,516,766

(4) The impact to the gross deferred tax assets balances as a result of tax-planning strategies as of December 31, 2024 and 2023 is presented below:

		202	2023			Chan				
		1		2		3	4	5		6
Impact of Tax-Planning Strategies		Ordinary		Capital		Ordinary	Capital	(Col 1 - 3) Ordinary		Col 2 - 4) Capital
 (a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets by tax character as a percentage. 										
Adjusted gross DTAs amount from Note 9A1(c)	\$	1,901,878	\$	_	\$	2,048,148	\$ _	\$ (146,270)	\$	_
Percentage of adjusted gross DTAs by tax character attributable to the impact of tax- planning strategies		— %		— %		— %	— %	- %		— %
Net admitted adjusted gross DTAs amount from Note 9A1(e)	\$	1,901,878	\$	_	\$	2,048,148	\$ _	\$ (146,270)	\$	_
 Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax-planning strategies 		— %		— %		— %	— %	— %		— %
(b) Does the Company's tax-planning strategies include the use of reinsurance?	Υє	es				Yes		No		Х

B. Unrecognized Deferred Tax Liabilities

(1–4) There are no unrecognized deferred tax liabilities for the years ended December 31, 2024 and 2023.

C. Significant Components of Income Taxes

(1) The current federal income taxes incurred for the years ended December 31, 2024 and 2023 are as follows:

1			2		3
2024		2023			(Col 1 - 2) Change
\$	21,658,225	\$	34,011,249	\$	(12,353,024)
	_				
					_
	21,658,225		34,011,249		(12,353,024)
	360,122		711		359,411
	_		_		_
\$	22,018,347	\$	34,011,960	\$	(11,993,613)
	\$	\$ 21,658,225 — 21,658,225 21,658,225 360,122 — —	\$ 21,658,225 \$ 21,658,225	2024 2023 \$ 21,658,225 \$ 34,011,249	2024 2023 \$ 21,658,225 \$ 34,011,249 \$

(2–4) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2024 and 2023, are as follows:

,	•				
	1	2			3
	2024	2023			(Col 1 - 2) Change
2. Deferred tax assets:	2024	2020			Onlange
(a) Ordinary:					
(1) Discounting of unpaid losses	\$ 408,723	\$ 44	7,594	\$	(38,871)
(2) Unearned premium reserve	1,542		1,752		(210)
(3) Policyholder reserves	_		_		_
(4) Investments	_		_		_
(5) Deferred acquisition costs	_		_		_
(6) Policyholder dividends accrual	_		_		_
(7) Fixed assets	_		_		_
(8) Compensation and benefits accrual	_		_		_
(9) Pension accrual	1 401 500	1.50	0.760		(107 170)
(10) Receivables — nonadmitted (11) Net operating loss carryforward	1,491,582	1,59	8,760		(107,178)
(11) Net operating loss carrylorward (12) Tax credit carryforward	_		_		_
(13) Other	31		42		(11)
	 				<u> </u>
(99) Subtotal (sum of 2a1 through 2a13)	1,901,878	2,04	8,148		(146,270)
(b) Statutory valuation allowance adjustment	_		_		_
(c) Nonadmitted	 			_	
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	 1,901,878	2,04	8,148		(146,270)
(e) Capital:					
(1) Investments	_		_		_
(2) Net capital loss carryforward	_		_		_
(3) Real estate	_		_		_
(4) Other	 				
(99) Subtotal (2e1+2e2+2e3+2e4)	_		_		_
(f) Statutory valuation allowance adjustment	_		_		_
(g) Nonadmitted					
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)					<u> </u>
(i) Admitted deferred tax assets (2d + 2h)	1,901,878	2,04	8,148		(146,270)
3. Deferred tax liabilities:					
(a) Ordinary:					
(1) Investments	_		_		_
(2) Fixed assets	_		_		_
(3) Deferred and uncollected premium	_		_		_
(4) Policyholder reserves	_		_		_
(5) Other	10,299	2	0,596		(10,297)
(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	10,299	2	0,596		(10,297)
(h) Conital	_				
(b) Capital: (1) Investments					
(2) Real estate					
(3) Other	_				_
(0) 04101	 	-			
(99) Subtotal (3b1+3b2+3b3)	 			_	
(c) Deferred tax liabilities (3a99 + 3b99)	 10,299	2	0,596		(10,297)
4. Net deferred tax assets/liabilities (2i - 3c)	\$ 1,891,579	\$ 2,02	7,552	\$	(135,973)

The Company assessed the potential realization of the gross deferred tax asset and as a result no statutory valuation allowance was required and no allowance was established as of December 31, 2024 and 2023.

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate of 21% to net income (loss) before federal income taxes. A summarization of the significant items causing this difference as of December 31, 2024 and 2023 is as follows:

	2024				2023				
		Amount	Effective Tax Rate		Amount	Effective Tax Rate			
Tax provision at the federal statutory rate	\$	22,081,524	21 %	\$	33,778,613	21 %			
Tax-exempt interest		(34,352)	_		(32,794)	_			
Tax effect of nonadmitted assets		107,148		_	(525,983)				
Total statutory income taxes	\$	22,154,320	21 %	\$	33,219,836	21 %			
Federal income taxes incurred	\$	21,658,225	21 %	\$	34,011,249	21 %			
Capital gains tax		360,122	_		711	_			
Change in net deferred income tax		135,973			(792,124)				
Total statutory income taxes	\$	22,154,320	21 %	\$	33,219,836	21 %			

E. At December 31, 2024, the Company had no net operating loss carryforwards.

Current federal income taxes recoverable of \$5,998,651 and \$2,382,039 as of December 31, 2024 and 2023, respectively, are included in the financial statements. Federal income taxes paid, net of refunds, were \$25,634,959 and \$34,139,271 in 2024 and 2023, respectively.

Federal income taxes incurred of \$22,018,347 and \$34,011,960 for 2024 and 2023, respectively, are available for recoupment in the event of future net losses.

The Company has not admitted any aggregate amounts of deposits that are included within Section 6603 ("Deposits made to suspend running of interest on potential underpayments, etc.") of the Internal Revenue Service Code.

- F. The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group Incorporated which constitutes a controlled group. The entities included within the consolidated return are included in the National Association of Insurance Commissioners' Statutory Statement Schedule Y Information Concerning Activities of Insurer Members Of A Holding Company Group. Federal income taxes are paid to or refunded by UnitedHealth Group Incorporated pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal return of UnitedHealth Group Incorporated. UnitedHealth Group Incorporated currently files income tax returns in the U.S. federal jurisdiction, various states, and foreign jurisdictions. The U.S. Internal Revenue Service has completed exams on UnitedHealth Group Incorporated's consolidated income tax returns for fiscal years 2016 and prior. UnitedHealth Group Incorporated's 2017 through 2020 tax returns are under review by the Internal Revenue Service under its Compliance Assurance Program. UnitedHealth Group Incorporated is no longer subject to income tax examinations prior to the 2015 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward.
- **G.** Tax Contingencies Not applicable.
- H. Repatriation Transition Tax Not applicable.
- I. Alternative Minimum Tax Credit Not applicable.

10. INFORMATION CONCERNING PARENT, SUBSIDIARIES, AND AFFILIATES

A–B. In the ordinary course of business, the Company contracts with several affiliates to provide a wide variety of services to the Company's members. These agreements are filed with and approved by the New Jersey Department of Banking and Insurance according to Management's understanding of the current requirements and standards. Within the confines of the applicable filed and approved agreements (including subsequent amendments thereto), the amount and types of services provided by these affiliated entities can change year over year.

United HealthCare Services, Inc. maintains a private short-term investment pool in which affiliated companies may participate (see Note 1). At December 31, 2024 and 2023, the Company's portion was \$53,584,561 and \$156,231,048, respectively and is included in cash equivalents in the financial statements.

The Company has a tax-sharing agreement with UnitedHealth Group Incorporated (see Note 9).

The Company paid dividends of \$75,000,000 and \$0 in 2024 and 2023, respectively, to its parent (see Note 13).

The Company holds a \$100,000,000 subordinated credit agreement with United HealthCare Services, Inc. at an interest rate of Fed Funds Target rate - Upper Bound plus 50 basis points. This credit agreement is subordinate to the claims of non-affiliated creditors and loans from non-affiliated lenders of the borrowers. This credit agreement is revolving, unless terminated by either party. No amounts were outstanding under the line of credit as of December 31, 2024 and December 31, 2023. There was no interest paid or accrued on all borrowings throughout the year as of December 31, 2024 and 2023, respectively.

- C. The Company has no material related party transactions that meet the disclosure requirements pursuant to Statement of Statutory Accounting Principles No. 25, Affiliates and Other Related Parties that are not included in National Association of Insurance Commissioner Statutory Statement Schedule Y—Part 2 Summary Of Insurer's Transactions With Any Affiliates.
- **D.** The Company had amounts due to parent, subsidiaries and affiliates of \$13,276,422 and \$25,975,873 as of December 31, 2024 and 2023, respectively, which are included in the financial statements. These balances are generally settled within 90 days from the incurred date. Any balances due to the Company that are not settled within 90 days are considered nonadmitted assets.
- E. The administrative services, access fees, and cost of care services provided by affiliates are calculated using one or more of the following methods: (1) a percentage of premiums; (2) use of assets; (3) direct pass-through of charges; (4) per member per month; (5) per employee per month; (6) per claim; or (7) a combination thereof consistent with the provisions contained in each contract. These amounts are included in general administrative expenses, claims adjustment expenses, and hospital and medical expenses in the financial statements. The following table identifies the amounts reported for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2024 and 2023, which meet the disclosure requirements pursuant to Statement of Statutory Accounting Principles No. 25, Affiliates and Other Related Parties, regardless of the effective date of the contract:

	2024	2023
Optum Health Networks, Inc.	\$ 651,112,130	\$ 753,912,021
OptumRx, Inc.	137,495,893	79,251,341
United HealthCare Services, Inc.	113,195,866	128,004,405
XLHome Northeast, P.C.	12,372,685	12,101,819
Optum Networks of New Jersey, Inc.	7,810,014	3,222,860
naviHealth, Inc.	6,352,573	6,771,398
United Behavioral Health	6,084,092	5,865,499
Optum Medical Care of New Jersey, P.C.	3,569,756	4,624,716
OptumInsight, Inc.	3,035,440	1,929,332
Landmark MSO, LLC	(19,576,460)	935,953

Optum Health Networks, Inc. provides services that may include, but are not limited to, care management services to eligible members and/or arranging for the delivery of clinical services to the Company's enrollees.

OptumRx, Inc. provides services that may include, but are not limited to, administrative services related to pharmacy management and pharmacy claims processing for enrollees, manufacturer rebate administration, pharmacy incentive services, specialty drug pharmacy services, durable medical equipment services including orthotics and prosthetics and personal health products catalogues showing the healthcare products and benefit credits enrollees needed to redeem the respective products.

United HealthCare Services, Inc. provides, or arranges for the provision of, management, administrative, and other services deemed necessary or appropriate for United HealthCare Services, Inc. to provide management and operational support to the Company. The services can include, but are not limited to, the categories of management and operational services outlined in the Agreement, such as human resources, legal, facilities, general administration, treasury and investment functions, claims adjudication and payment, benefit administration, disease management, health care decision support, medical management, credentialing, preventative health services, utilization management reporting and expenses incurred for new business that will be effective in the subsequent year.

XLHome Northeast, P.C. provides house call services to the Company's members.

Optum Networks of New Jersey, Inc. provides medical management services for subscribers or enrollees of managed care plans.

naviHealth, Inc. provides comprehensive post-acute services and care delivery.

United Behavioral Health provides services related to mental health and substance abuse treatment.

Optum Medical Care of New Jersey, P.C. provides medical assistance for children.

OptumInsight, Inc. provides services that may include, but are not limited to, coordination of benefits and data mining, Retrospective Fraud and Waste Abuse, subrogation and audit services. All recoveries are returned to the Company by OptumInsight, Inc. on a monthly basis.

Landmark MSO, LLC PA provides delivery of home-based medical care to improve the health and quality of care for chronically ill and frail individuals.

The Company has premium payments that are received and claim payments and direct expenses such as broker commissions, New Jersey Department of Banking and Insurance exam fees, Affordable Care Act assessments and premium taxes that are processed and paid by an affiliated UnitedHealth Group Incorporated entity. Premiums, claims, and direct expenses applicable to the Company are settled at regular intervals throughout the month via the intercompany settlement process and any amounts outstanding are reflected in amounts due to parent, subsidiaries, and affiliates in the financial statements.

- **F.** The Company has not extended any guarantees or undertakings for the benefit of an affiliate or related party.
- **G.** The Company is part of an insurance holding company system with UnitedHealth Group Incorporated as the ultimate parent. Management believes that the Company's transactions with affiliates are fair and reasonable; however, operations of the Company may not be indicative of those that would have occurred if it had operated as an independent company.
- **H.** The Company does not have any amount deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream subsidiary, controlled, or affiliated entity.
- I. The Company does not have any investments in a subsidiary, controlled, or affiliated entity that exceeds 10% of admitted assets.
- J. The Company does not have any investments in impaired subsidiaries, controlled, or affiliated entities.
- K. The Company does not have any investments in foreign insurance subsidiaries.
- L. The Company does not hold any investments in a downstream noninsurance holding company.
- **M.** The Company does not have any investments in noninsurance subsidiaries, controlled, or affiliated entities.
- **N.** The Company does not have any investments in insurance subsidiaries, controlled, or affiliated entities.
- O. The Company does not have any investments in subsidiary, controlled, or affiliated entities or joint ventures, partnerships, and limited liability companies in which the Company's share of losses exceeds the investment.

11. DEBT

A–B. The Company had no outstanding debt with third-parties or outstanding Federal Home Loan Bank agreements during 2024 and 2023.

12. RETIREMENT PLANS, DEFERRED COMPENSATION, POSTEMPLOYMENT BENEFITS AND COMPENSATED ABSENCES AND OTHER POSTRETIREMENT BENEFIT PLANS

A–I. The Company has no defined benefit plans, defined contribution plans, multiemployer plans, consolidated/holding company plans, postemployment benefits, or compensated absences plans and is not impacted by the Medicare Modernization Act on postretirement benefits, since all personnel are employees of United HealthCare Services, Inc., which provides services to the Company under the terms of the management agreement (see Note 10).

13. CAPITAL AND SURPLUS, DIVIDEND RESTRICTIONS, AND QUASI-REORGANIZATIONS

- **A–B.** The Company has 1,000 shares authorized and 500 shares issued and outstanding of \$0.10 par value common stock. The Company has no preferred stock outstanding. All issued and outstanding shares of common stock are held by the Company's parent, Oxford Health Plans, LLC.
- **C.** Dividend payment requirements are outlined in the domiciliary state statutes and may be further restricted by the New Jersey Department of Banking and Insurance.
- **D.** The Company paid an ordinary cash dividend of \$75,000,000 on March 15, 2024 to Oxford Health Plans, LLC, which was approved by the New Jersey Department of Banking and Insurance and recorded as a reduction to unassigned funds (surplus) in the financial statements.
- **E.** The amount of ordinary dividends that may be paid out during any given period is subject to certain restrictions as specified by state statute.
- **F.** There are no restrictions placed on the Company's unassigned funds (surplus).
- **G.** The Company is not a mutual reciprocal or a similarly organized entity and does not have advances to surplus not repaid.
- **H.** The Company does not hold any stock, including stock of affiliated companies for special purposes, such as conversion of preferred stock, employee stock options, or stock purchase warrants.
- I. The Company does not have any special surplus funds.

J. The portion of unassigned funds (surplus), excluding net income (loss) and dividends, represented (or reduced) by each item below is as follows:

	2024	2023
Net deferred income taxes	1,891,579	2,027,552
Nonadmitted assets	(7,102,979)	(7,613,209)
Total	\$ (5,211,400)	\$ (5,585,657)

K–M. The Company does not have any outstanding surplus notes and has never been a party to a quasi-reorganization.

14. LIABILITIES, CONTINGENCIES AND ASSESSMENTS

A. Contingent Commitments

The Company has no contingent commitments.

B. Assessments

The Company is not aware of any guaranty fund assessments or premium tax offsets, potential or accrued, that could have a material financial effect on the operations of the entity.

C. Gain Contingencies

The Company is not aware of any gain contingencies that should be disclosed in the financial statements.

- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits Not applicable.
- E. Joint and Several Liabilities Not applicable.

F. All Other Contingencies

The Company's business is regulated at the federal, state, and local levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The Company has been, or is currently involved, in various governmental investigations, audits and reviews. These include routine, regular, and special investigations, audits and reviews by Centers for Medicare and Medicaid Services, state insurance and health and welfare departments and other governmental authorities. The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

On February 14, 2017, the Department of Justice announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company's motion to dismiss. In May 2018, the Department of Justice moved to dismiss the Company's counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government's motion for partial summary judgment and dismissed the Company's counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers, and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters involve: indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility, or it is probable that a loss may be incurred. Although the outcomes of any such legal actions cannot be predicted, in the opinion of management, the resolution of any currently pending or threatened actions will not have a material adverse effect on the financial statements of the Company.

The Company routinely evaluates the collectability of all receivable amounts included in the financial statements. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Company's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Company's statutory basis financial condition.

There are no assets that the Company considers to be impaired at December 31, 2024 and 2023.

15. LEASES

A–B. According to the management agreement between the Company and United HealthCare Services, Inc. (see Note 10), United HealthCare Services, Inc. is responsible for operating leases for the rental of office facilities and equipment. Fees associated with the lease agreements are included as a component of the Company's management fee.

16. INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK

(1–4) The Company does not hold any financial instruments with off-balance-sheet risk or have any concentrations of credit risk.

17. SALE, TRANSFER, AND SERVICING OF FINANCIAL ASSETS AND EXTINGUISHMENTS OF LIABILITIES

A–C. The Company did not participate in any transfer of receivables, financial assets, or wash sales.

18. GAIN OR LOSS TO THE REPORTING ENTITY FROM UNINSURED PLANS AND THE UNINSURED PORTION OF PARTIALLY INSURED PLANS

A–B. The Company has no operations from Administrative Services Only Contracts or Administrative Services Contracts in 2024 and 2023.

C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Medicare Part D program is a partially insured plan. The Company recorded a payable of \$3,345,443 and \$21,712,159 at December 31, 2024 and 2023, respectively, for cost reimbursement under the Medicare Part D program for the catastrophic reinsurance and low-income member cost-sharing subsidies. The Company also recorded a receivable of \$33,936 and \$63,980 and also a payable of \$0 and \$52,528 at December 31, 2024 and 2023, respectively, for the Medicare Part D coverage gap discount program. The receivables and payables are recorded in amounts receivable relating to uninsured plans and liability for amounts held under uninsured plans, respectively, in the financial statements.

The Inflation Reduction Act was signed into law in 2022 and created a one-year subsidy for 2023 labeled as the Inflation Reduction Act Subsidy Amounts. The Company recorded a receivable of \$22,718 at December 31, 2024 for the temporary retrospective subsidy be paid to Part D plans for the reduction in cost sharing and elimination of the deductible for ACIP-recommended vaccines and covered insulin products during the 2023 plan year related to Inflation Reduction Act Subsidy Amounts. The Inflation Reduction Act Subsidy was only available for 2023.

19. DIRECT PREMIUM WRITTEN/PRODUCED BY MANAGING GENERAL AGENTS/THIRD-PARTY ADMINISTRATORS

The Company did not have any direct premiums written or produced by managing general agents or third-party administrators in 2024 and 2023.

20. FAIR VALUE MEASUREMENTS

The National Association of Insurance Commissioner Practices and Procedures manual defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1 — Quoted (unadjusted) prices for identical assets in active markets.

Level 2 — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3 — Unobservable inputs that cannot be corroborated by observable market data.

The estimated fair values of bonds, cash equivalents, and short-term investments are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service ("pricing service"), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant, and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in an adjustment in the prices obtained from the pricing service.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

A. Fair Value

(1) Fair Value Measurements at Reporting Date

The following tables present information about the Company's financial assets that are measured and reported at fair value at December 31, 2024 and 2023, in the financial statements according to the valuation techniques the Company used to determine their fair values:

						2024				
	Description for Each Class of Asset or Liability	(Level 1)		(Level 2)		(Level 3)	١	t Asset /alue NAV)		Total
a.	Assets at fair value:									
	Perpetual preferred stock:									
	Industrial and misc	\$ —	\$	_	\$	_	\$	_	\$	_
	Parent, subsidiaries, and affiliates				_				_	
	Total perpetual preferred stocks		_		_					
	Bonds:									
	U.S. governments	_		_		_		_		_
	Industrial and misc	_		_		_		_		_
	Hybrid securities	_		_		_		_		_
	Parent, subsidiaries, and affiliates		_		_					
	Total bonds		_							
	Common stock:									
	Industrial and misc	_		_		_		_		_
	Parent, subsidiaries, and affiliates		_		_					
	Total common stock		_							
	Derivative assets:									
	Interest rate contracts	_		_		_		_		_
	Foreign exchange contracts	_		_		_		_		_
	Credit contracts	_		_		_		_		_
	Commodity futures contracts	_		_		_		_		_
	Commodity forward contracts		_		_				_	
	Total derivatives		_		_					
	Money-market funds	8,540,112		_		_		_		8,540,112
	Qualified cash pool	53,584,561	_						_	53,584,561
	Total assets at fair value/NAV	\$ 62,124,673	\$		\$		\$		\$	62,124,673
b.	Liabilities at fair value:									
	Derivative liabilities	\$	\$		\$		\$		\$	
	Total liabilities at fair value	\$ _	\$		\$		\$		\$	

			2023		
Description for Each Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value:					
Perpetual preferred stock:					
Industrial and misc	\$ —	\$ —	\$ —	\$	\$ —
Parent, subsidiaries, and affiliates					
Total perpetual preferred stocks					
Bonds:					
U.S. governments	_	_	_	_	_
Industrial and misc	_	_	_	_	_
Hybrid securities	_	_	_	_	_
Parent, subsidiaries, and affiliates	_	_	_	_	_
Total bonds					
Common stock:					
Industrial and misc	_	_	_	_	_
Parent, subsidiaries, and affiliates					
Total common stock					
Derivative assets:					
Interest rate contracts	_	_	_	_	_
Foreign exchange contracts	_	_	_	_	_
Credit contracts	_	_	_	_	_
Commodity futures contracts	_	_	_	_	_
Commodity forward contracts					
Total derivatives					
Money-market funds	5,678,993	_	_	_	5,678,993
Qualified cash pool	156,231,048				156,231,048
Total assets at fair value/NAV	\$ 161,910,041	<u>\$</u>	· <u>\$</u>	<u> </u>	\$ 161,910,041
b. Liabilities at fair value:					
Derivative liabilities	<u> </u>	<u> </u>	\$	<u> </u>	<u> </u>
Total liabilities at fair value	<u> </u>	\$	<u>\$</u>	<u> </u>	<u> </u>

- (2) The Company does not have any financial assets with a fair value hierarchy of Level 3 that were measured and reported at fair value.
- (3) Transfers between fair value hierarchy levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2024 or 2023.
- (4) The Company has no investments reported with a fair value hierarchy of Level 2 or Level 3 and therefore has no valuation technique to disclose.
- (5) The Company has no derivative assets and liabilities to disclose.
- **B.** Fair Value Combination Not applicable.

C. Aggregate Fair Value Hierarchy

The aggregate fair value by hierarchy of all financial instruments as of December 31, 2024 and 2023 is presented in the table below:

				2024			
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
U.S. government and agency securities	\$ 129,390,856	\$ 130,757,127	\$ 114,899,472	\$ 14,491,384	\$ _	\$ —	\$ _
State and agency municipal securities	5,718,243	5,737,276	_	5,718,243	_	_	_
City and county municipal securities	3,903,411	3,937,451	_	3,903,411	_	_	_
Corporate debt securities	108,961,409	109,118,069	_	108,961,409	_	_	_
Cash equivalents	91,401,828	91,401,828	91,401,828	_	_	_	_
Total bonds, short-term investments, and							
cash equivalents	\$ 339,375,747	\$ 340,951,751	\$ 206,301,300	\$ 133,074,447	<u> </u>	<u> </u>	<u> </u>
				2023			
Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value	Not Practicable (Carrying
			,	(Level 2)	(Level 3)	(NAV)	`Value)
U.S. government and agency securities	\$ 72,906,929	\$ 73,683,833	\$ 60,744,217	\$ 12,162,712	(Level 3)	(NAV) \$ —	value)
U.S. government and agency securities State and agency municipal securities	\$ 72,906,929 4,746,708	\$ 73,683,833 4,769,786	, ,	, ,	` ,	, ,	,
0 ,			, ,	\$ 12,162,712	` ,	, ,	,
State and agency municipal securities	4,746,708	4,769,786	, ,	\$ 12,162,712 4,746,708	` ,	, ,	,
State and agency municipal securities City and county municipal securities	4,746,708 5,527,605	4,769,786 5,592,668	, ,	\$ 12,162,712 4,746,708 5,527,605	` ,	, ,	·
State and agency municipal securities City and county municipal securities Corporate debt securities	4,746,708 5,527,605 125,301,274	4,769,786 5,592,668 126,607,850	\$ 60,744,217 — —	\$ 12,162,712 4,746,708 5,527,605	` ,	, ,	,

- D. Not Practicable to Estimate Fair Value Not applicable.
- E. Investments Measured Using the NAV Practical Expedient Not applicable.

21. OTHER ITEMS

A. Unusual or Infrequent Items

The Company did not encounter any unusual or infrequent items for the years ended December 31, 2024 and 2023.

B. Troubled Debt Restructuring: Debtors

The Company has no troubled debt restructurings as of December 31, 2024 and 2023.

C. Other Disclosures

The Company does not have any amounts not recorded in the financial statements that represent segregated funds held for others. The Company also does not have any exposures related to forward commitments that are not derivative instruments.

D. Business Interruption Insurance Recoveries

The Company has not received any business interruption insurance recoveries during 2024 and 2023.

E. State Transferable and Non-transferable Tax Credits

The Company has no transferable or non-transferable state tax credits.

F. Sub-Prime Mortgage-Related Risk Exposure

(1-4) The investment policy for the Company limits investments in loan-backed securities, which can include sub-prime issuers. Further, the policy limits investments in private issuer mortgage securities to 10% of the portfolio, which also includes sub-prime issuers. The Company does not have any sub-prime mortgage-related risk exposure as of December 31, 2024 and 2023.

G. Retained Assets

The Company does not have any retained asset accounts for beneficiaries.

H. Insurance-Linked Securities Contracts

As of December 31, 2024, the Company is not aware of any possible proceeds of insurance-linked securities.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy — Not applicable.

22. EVENTS SUBSEQUENT

Subsequent events have been evaluated through February 28, 2025, which is the date these financial statements were available for issuance.

TYPE I — Recognized Subsequent Events

Any material Type I events subsequent to December 31, 2024, have been recognized in the financial statements and corresponding disclosures.

TYPE II — Non-Recognized Subsequent Events

On February 13, 2025, the Company declared an ordinary cash dividend of \$50,000,000 to the sole shareholder, Oxford Health Plans, LLC. The ordinary dividend complied with the provisions set forth in the statutes of New Jersey. The dividend is expected to be paid from unassigned funds (surplus) on March 17, 2025.

There are no other material non-recognized Type II events that require disclosure.

23. REINSURANCE

- **A–D.** The Company does not have any material affiliated or unaffiliated reinsurance agreements in place as of December 31, 2024 or 2023.
- E. Reinsurance Credit Not applicable.

24. RETROSPECTIVELY RATED CONTRACTS AND CONTRACTS SUBJECT TO REDETERMINATION

- **A.** The Company estimates accrued retrospective premium adjustments for its group health insurance business based on mathematical calculations in accordance with contractual terms.
- **B.** Estimated accrued retrospective premiums due to (from) the Company are recorded in premiums and considerations and aggregate health policy reserves in the financial statements and as an adjustment to change in unearned premium reserves and reserve for rate credits in the financial statements.
- C. Pursuant to the Affordable Care Act, the Company's commercial and Medicare business is subject to retrospectively rated features based on the actual medical loss ratio experienced on the commercial and Medicare lines of business and redetermination features for premium adjustments for changes to each member's health scores based on guidelines determined by the Affordable Care Act. The total amount of direct premiums written for which a portion is subject to the retrospectively rated and redetermination features are \$758,051 and \$572,912 for commercial, and \$1,996,552,402 and \$2,023,589,405 for Medicare, representing less than 1% for commercial, and 99% for Medicare of total direct premiums written as of December 31, 2024 and 2023 respectively.

The Company has Medicare Part D risk-corridor amounts from the Centers for Medicare and Medicaid Services which are subject to a retrospectively rated feature. The Company has estimated accrued retrospective premiums related to certain Part D premiums based on guidelines determined by the Centers for Medicare and Medicaid Services. The formula is tiered and based on the bid medical loss ratio. The amount of Medicare Part D direct premiums subject to the retrospectively rated feature was \$133,510,304 and \$69,928,059, representing 7% and 3% of total direct premiums written as of December 31, 2024 and 2023, respectively.

D. The Company is required to maintain specific minimum medical loss ratios on the comprehensive commercial and Medicare lines of business.

The Company's actual loss ratios on the comprehensive commercial line of business was in excess of the minimum requirements and as a result, no minimum medical loss ratio rebate liability was required to be established at December 31, 2024 and 2023.

The following table discloses the minimum medical loss ratio rebate liability for the Medicare line of business which is included in aggregate health policy reserves in the financial statements for the years ended December 31, 2024 and 2023:

	1	1		2				4	5
	Individua	Individual		ıp	Large Empl		Cat	Other egories with Rebates	Total
Prior reporting year									
(1) Medical loss ratio rebates incurred	\$	_	\$	_	\$	_	\$	(3,148,689)	\$ (3,148,689)
(2) Medical loss ratio rebates paid		_		_		_		2,676,151	2,676,151
(3) Medical loss rebates unpaid		_		_		_		5,067,940	5,067,940
(4) Plus reinsurance assumed amounts	XXX		XXX		X	ΚX		XXX	_
(5) Less reinsurance ceded amounts	XXX		XXX		X	ΚX		XXX	_
(6) Rebates unpaid net of reinsurance	XXX		XXX		X	(X		XXX	5,067,940
Current reporting year-to-date									
(7) Medical loss ratio rebates incurred		_		_		_		272	272
(8) Medical loss ratio rebates paid		_		_		_		5,068,212	5,068,212
(9) Medical loss rebates unpaid		_		_		_		_	_
(10) Plus reinsurance assumed amounts	XXX		XXX		X	ΚX		XXX	_
(11) Less reinsurance ceded amounts	XXX		XXX		X	ΚX		XXX	_
(12) Rebates unpaid net of reinsurance	XXX		XXX		X	ΚX		XXX	_

In addition to the Affordable Care Act minimum medical loss ratio requirements, all Corporations and health maintenance organizations that filed for any rate adjustment in any prior calendar year shall submit, no later than August 1, a report showing loss ratios for the previous calendar year for small group and individual direct pay standardized business. For small group and individual direct pay contracts a minimum medical loss ratio of 80% must be met. The Company had no estimated minimum medical loss ratio rebates payable as of December 31, 2024 and 2023, respectively. The Company paid out approximately \$171,024 and \$333,456 relating to the 2023 and 2022 small group loss ratio filings in 2024 and 2023, which was filed with the New Jersey Department of Banking and Insurance.

E. Risk-Sharing Provisions of the Affordable Care Act

(1) The Company has accident and health insurance premiums in 2024 and 2023 subject to the Affordable Care Act risk-sharing provisions for the permanent risk adjustment program.

The risk adjustment program is a permanent program designed to mitigate the potential impact of adverse selection that generally applies to non-grandfathered individual and small group plans inside and outside of exchanges. The program helps to stabilize market premiums by transferring funds from plans with relatively low-risk enrollees to plans with relatively high-risk enrollees. The data used by the Centers for Medicare and Medicaid Services to determine the risk adjustment transfer amount is subject to audits along with the true-up to the final Centers for Medicare and Medicaid Services report, which may result in a material change to arrive at the final risk adjustment amount from the initial risk adjustment estimate recorded. Premium adjustments pursuant to the risk adjustment program are accounted for as premium subject to redetermination and user fees are accounted for as assessments.

(2) The following table presents the current year impact for the permanent risk adjustment program regarding the risk-sharing provisions of the Affordable Care Act on assets, liabilities, and operations:

Permanent ACA Risk Adjustment Program	2024
<u>Assets</u>	
 Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) 	\$ 2,121
<u>Liabilities</u>	
2. Risk adjustment user fees payable for ACA Risk Adjustment	390
Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premium)	355,231
Operations (Revenue & Expense)	
Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	(416,790)
5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	390

(3) The following table is a roll forward of the prior year Affordable Care Act risk-sharing provisions for the permanent risk adjustment program for asset and liability balances, along with reasons for adjustments to prior year balances:

											Differ	enc	es		Adjust	men	ts			Insettled I the Rep		ances as ing Date	
			Accrued the Pri on Busine before De of the P	or Ye ss W cemb	ar ritten er 31		Received or the Curro on Busine before Dec of the Pr	ent ss '	t Year Written nber 31	F	Prior YeaR Accrued Less Payments (Col 1 - 3)		Prior Year Accrued Less Payments (Col 2 - 4)		To Prior Year Balances		Prior Year Balances		B	mulative Balance from or Years I 1 - 3 + 7))	Cumula Balan fron Prior Y (Col 2 -	nce n ears
			1		2		3		4		5		6		7		8			9		10	
		Red	eivable	(1	Payable)	R	eceivable		(Payable)	R	Receivable		(Payable)	Re	eceivable	(Payable)	Ref	Re	ceivable		(Payal	ole)
a.	Permanent ACA Risk Adjustment Program																						
	Premium adjustment receivable (including high risk pool payments)	\$	2,611	\$	_	\$	754	\$	_	\$	1,857	\$	_	\$	(1,857)	\$	_	Α	\$	_	-	\$	_
	Premium adjustment (payable) (including high risk pool premium)				(535,818)				(597,641)				61,823				(62,367)	В		_			(544)
	Total ACA Permanent Risk Adjustment Program		2,611		(535,818)		754		(597,641)		1,857		61,823		(1,857)		(62,367)			_	_		(544)

Explanation of Adjustments

a.

The risk adjustment receivable as of December 31, 2023 utilized paid claims through October 31, 2023. As of the Reporting Date, the risk adjustment receivable related to prior periods was adjusted based on CMS Summary Report on Individual and Small Group Market Risk Transfers for the 2023 Benefit Year. The risk adjustment receivable was further adjusted based on CMS' Summary Report of 2022 Benefit Year Risk A. Adjustment Data Validation (HHS-RADV) Adjustments to Risk Adjustment State Transfers.

The risk adjustment payable as of December 31, 2023 utilized paid claims through October 31, 2023. As of the Reporting Date, the risk adjustment payable related to prior periods was adjusted based on CMS' Summary Report on Individual and Small Group Market Risk Transfers for the 2023 Benefit Year. The risk adjustment payable was further adjusted based on CMS' Summary Report of 2022 Benefit Year Risk Adjustment Data

25. CHANGE IN INCURRED CLAIMS AND CLAIMS ADJUSTMENT EXPENSES

A. Changes in estimates related to the prior year incurred claims are included in total hospital and medical expenses in the current year in the financial statements. The following tables disclose paid claims, incurred claims, and the balance in claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, and health care and other amounts receivable (excluding provider loans and advances not yet expensed) for the years ended December 31, 2024 and 2023:

		2024	
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve	\$ _	\$ (147,503,652)	\$ (147,503,652)
Paid claims — net of health care receivables*	1,709,422,321	40,693,873	1,750,116,194
End of year claim reserve	133,428,467	4,038,047	137,466,514
Incurred claims excluding the change in health care receivables as presented below	1,842,850,788	(102,771,732)	1,740,079,056
Beginning of year health care receivables*	_	97,470,247	97,470,247
End of year health care receivables*	 (93,413,266)	 (3,909,575)	(97,322,841)
Total incurred claims	\$ 1,749,437,522	\$ (9,211,060)	\$ 1,740,226,462

^{*}Health care receivables excludes provider loans and advances not yet expensed of \$2,141,438 and \$2,593,348 for 2024 and 2023, respectively.

		2023	
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve	\$ _	\$ (67,593,887)	\$ (67,593,887)
Paid claims — net of health care receivables* End of year claim reserve	1,635,957,711 144,832,772	1,028,527 2,670,880	1,636,986,238 147,503,652
Incurred claims excluding the change in health care receivables as presented below	1,780,790,483	(63,894,480)	1,716,896,003
Beginning of year health care receivables	_	71,168,827	71,168,827
End of year health care receivables*	 (93,982,426)	(3,487,821)	 (97,470,247)
Total incurred claims	\$ 1,686,808,057	\$ 3,786,526	\$ 1,690,594,583

^{*}Health care receivables excludes provider loans and advances not yet expensed of \$2,593,348 and \$0 for 2023 and 2022, respectively.

The liability for claims unpaid, accrued medical incentive pool and bonus amounts, and aggregate health claim reserves, net of health care and other amounts receivable (excluding provider loans and advances not yet expensed) as of December 31, 2023 was \$50,033,405. As of December 31, 2024, \$40,693,873 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, net of health care and other amounts receivable (excluding provider loans and advances not yet expensed) are now \$128,472, as a result of re-estimation of unpaid claims. Therefore, there has been \$9,211,060 favorable prior year development since December 31, 2023 to December 31, 2024. The primary drivers consist of favorable development as a result of a change in the provision for adverse deviations in experience of \$6,966,120, favorable development of \$3,072,016 in capitation, and favorable development of \$2,894,729 in pharmacy rebates offset by unfavorable development of \$3,379,967 in Medicare Part D expenses, and unfavorable development of \$1,057,523 in retroactivity for inpatient, outpatient, physician, and pharmacy claims.

At December 31, 2023, the Company recorded \$3,786,526 of unfavorable development. The primary drivers consist of unfavorable development of \$2,891,532 in retroactivity for inpatient, outpatient, physician, and pharmacy claims, unfavorable development of \$2,854,790 in risk share, and unfavorable development of \$1,709,879 in capitation, partially offset by favorable development of \$4,017,595 as a result of a change in provision for adverse deviations in experience. Original estimates are increased or decreased as additional information becomes known regarding individual claims, which could have an impact to the accruals for medical loss ratio rebates and retrospectively rated contracts. As a result of the prior year effects, on a regular basis, the Company adjusts revenue and the corresponding liability and/or receivable related to retrospectively rated policies and the impact of the change is included as a component of change in unearned premium reserves and reserve for rate credits in the financial statements.

The Company incurred claims adjustment expenses of \$58,474,161 and \$58,327,080 in 2024 and 2023, respectively. These costs are included in the management service fees paid by the Company to United HealthCare Services, Inc. as a part of the management agreement (see Note 10). The following table discloses paid claims adjustment expenses, incurred claims adjustment expenses, and the balance in unpaid claims adjustment expenses reserve for 2024 and 2023:

	2024	2023
Total claims adjustment expenses	\$ 58,474,161	\$ 58,327,080
Less: current year unpaid claims adjustment expenses	(1,525,983)	(1,618,284)
Add: prior year unpaid claims adjustment expenses	1,618,284	1,132,105
Total claims adjustment expenses paid	\$ 58,566,462	\$ 57,840,901

B. The Company did not make any significant changes in methodologies and assumptions used in the calculation of the liability for claims unpaid and unpaid claims adjustment expenses in 2024.

26. INTERCOMPANY POOLING ARRANGEMENTS

A-G. The Company did not have any intercompany pooling arrangements in 2024 or 2023.

27. STRUCTURED SETTLEMENTS

A-B. The Company did not have structured settlements in 2024 or 2023.

28. HEALTH CARE AND OTHER AMOUNTS RECEIVABLE

A. Pharmacy rebates receivable are recorded when reasonably estimated or billed by the affiliated pharmaceutical benefit manager in accordance with pharmaceutical rebate contract provisions. Information used to support rebates billed to the manufacturer is based on utilization information gathered by the pharmaceutical benefit manager and adjusted for significant changes in pharmaceutical contract provisions.

The Company evaluates admissibility of all pharmacy rebates receivable based on the administration of each underlying pharmaceutical benefit management agreement. The Company has nonadmitted and excluded all pharmacy rebates receivable that do not meet the admissibility criteria of Statement of Statutory Accounting Principles No. 84, *Health Care and Government Insured Plan Receivables* from the financial statements.

For each pharmaceutical management agreement for which a portion of the total pharmacy rebates receivable can be admitted based on the admissibility criteria of Statement of Statutory Accounting Principles No. 84, *Health Care and Government Insured Plan Receivables*, the pharmacy rebate transaction history is summarized as follows:

Quarter	Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Re	Actual bates Received within 90 Days of Billing	Re	Actual ebates Received within 91 to 180 Days of Billing	Ī	Actual Rebates Received More than 180 Days After Billing
12/31/2024	\$ 66,422,610	\$ 22,881,420	\$	_	\$	_	\$	_
9/30/2024	66,651,122	68,588,745		41,222,378		_		_
6/30/2024	64,312,071	67,048,681		49,276,966		14,619,107		_
3/31/2024	61,918,520	64,591,838		50,444,660		11,249,918		813,390
12/31/2023	68,081,255	69,023,843		59,738,163		8,373,224		728,581
9/30/2023	66,905,025	66,234,150		59,557,373		5,882,770		710,097
6/30/2023	62,200,902	62,028,050		54,414,007		6,603,594		913,506
3/31/2023	56,104,366	56,294,034		47,308,882		8,850,722		39,302
12/31/2022	49,015,049	48,374,195		44,481,539		3,717,857		175,029
9/30/2022	47,187,987	46,900,149		43,721,507		2,881,345		297,680
6/30/2022	44,313,893	44,001,352		38,546,196		4,755,997		699,048
3/31/2022	41,360,714	40,821,340		34,999,346		4,935,045		887,256

Of the amount reported as health care and other amounts receivable, \$91,318,268 and \$91,751,108 relate to pharmacy rebates receivable as of December 31, 2024 and 2023, respectively.

B. The Company has nonadmitted all risk-sharing receivables from the financial statements.

The Company also admitted \$346,464 and \$749,367 of provider receivables resulting from claim overpayments and \$868,885 and \$0 resulting from capitation arrangements as of December 31, 2024 and December 31, 2023, respectively, which are included in health care and other amounts receivable in the financial statements.

29. PARTICIPATING POLICIES

The Company did not have any participating contracts in 2024 or 2023.

30. PREMIUM DEFICIENCY RESERVES

The Company has not recorded any premium deficiency reserves as of December 31, 2024 or 2023. The analysis of premium deficiency reserves was completed as of December 31, 2024 and 2023. The Company did consider anticipated investment income when calculating the premium deficiency reserves.

The following table summarizes the Company's premium deficiency reserves as of December 31, 2024 and 2023:

2024

	2024	
Liability carried for premium deficiency reserves	\$	_
2. Date of the most recent evaluation of this liability	12/31/2024	
3. Was anticipated investment income utilized in this calculation?	Yes X No	
	2023	
Liability carried for premium deficiency reserves	\$	_
2. Date of the most recent evaluation of this liability	12/31/2023	
3. Was anticipated investment income utilized in this calculation?	Yes X No	

31. ANTICIPATED SALVAGE AND SUBROGATION

Due to the type of business being written, the Company has no salvage. As of December 31, 2024 and 2023, the Company had no specific accruals established for outstanding subrogation, as it is considered a component of the actuarial calculations used to develop the estimates of claims unpaid and aggregate health claim reserves.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company Syste is an insurer?		
1.2	If yes, did the reporting entity register and file with its domiciliary State Insuch regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the its Model Insurance Holding Company System Regulatory Act and mode subject to standards and disclosure requirements substantially similar to	ne Holding Company System, a registration statement National Association of Insurance Commissioners (NAIC) in I regulations pertaining thereto, or is the reporting entity	[X] No [] N/A []
1.3	State Regulating?		New Jersey
1.4	Is the reporting entity publicly traded or a member of a publicly traded gro	oup?	Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code is:	sued by the SEC for the entity/group	0000731766
2.1	Has any change been made during the year of this statement in the charreporting entity?		Yes [] No [X]
2.2	If yes, date of change:		
3.1	State as of what date the latest financial examination of the reporting ent	ity was made or is being made	12/31/2021
3.2	State the as of date that the latest financial examination report became a entity. This date should be the date of the examined balance sheet and n		12/31/2021
3.3	State as of what date the latest financial examination report became avail domicile or the reporting entity. This is the release date or completion date examination (balance sheet date).	te of the examination report and not the date of the	05/10/2023
3.4	By what department or departments? New Jersey Department of Banking and Insurance		
3.5	Have all financial statement adjustments within the latest financial exami statement filed with Departments?		[] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination r	eport been complied with? Yes	[X] No [] N/A []
4.1		es of the reporting entity) receive credit or commissions for or contro	Yes [] No [X]
4.2	During the period covered by this statement, did any sales/service organi receive credit or commissions for or control a substantial part (more than premiums) of:	zation owned in whole or in part by the reporting entity or an affiliate 20 percent of any major line of business measured on direct),
		of new business?als?	
5.1	Has the reporting entity been a party to a merger or consolidation during If yes, complete and file the merger history data file with the NAIC.	the period covered by this statement?	Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC company code, and state of ceased to exist as a result of the merger or consolidation.	domicile (use two letter state abbreviation) for any entity that has	
	1 Name of Entity	2 3 NAIC Company Code State of Domicile	
6.1	Has the reporting entity had any Certificates of Authority, licenses or regirevoked by any governmental entity during the reporting period?		
6.2	If yes, give full information		
7.1	Does any foreign (non-United States) person or entity directly or indirectly		
7.2	If yes, 7.21 State the percentage of foreign control	entity is a mutual or reciprocal, the nationality of its manager or	0.0 %
	attorney-in-fact and identify the type of entity(s) (e.g., individual, cor 1 Nationality	poration, government, manager or attorney-in-ract). 2 Type of Entity	

8.1 8.2	Is the company a subsidiary of a depository institution holding compa If the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No [Х]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities of response to 8.3 is yes, please provide below the names and location federal financial regulatory services agency [i.e. the Federal Reserve Federal Deposit Insurance Corporation (FDIC) and the Securities Excregulator.	ons (city and state of the main office) of any affiliates Board (FRB), the Office of the Comptroller of the Cu change Commission (SEC)] and identify the affiliate's	regulated	d by a DCC), th		Yes [X]	No []
	1	2	3	4	5	6			
	Affiliate Name Optum Bank, Inc	Location (City, State)	FRB NO	OCC N0	FDIC YES		-		
	Optuli Bank, Inc.		-		120				
8.5	Is the reporting entity a depository institution holding company with significant Reserve System or a subsidiary of the depository institution h					Yes [1	No I	X 1
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiar Federal Reserve Board's capital rule?	y of a company that has otherwise been made subje	ct to the	Υ] No [•	-
9.	What is the name and address of the independent certified public acc	countant or accounting firm retained to conduct the a	nnual au	dit?					
10.1	Deloitte & Touche LLP, Minneapolis, MN Has the insurer been granted any exemptions to the prohibited non-a requirements as allowed in Section 7H of the Annual Financial Report	udit services provided by the certified independent prting Model Regulation (Model Audit Rule), or substant	ublic acc ntially sin	ountant nilar sta	te	V [,	Na T	v i
10.2	law or regulation?	nption:				Yes [J	NO [x]
10.3	Has the insurer been granted any exemptions related to the other req allowed for in Section 18A of the Model Regulation, or substantially si If the response to 10.3 is yes, provide information related to this exem	uirements of the Annual Financial Reporting Model Fimilar state law or regulation?	Regulatio	n as		Yes []	No [Х]
10.1									
10.5 10.6	Has the reporting entity established an Audit Committee in compliance of the response to 10.5 is no or n/a, please explain.	e with the domiciliary state insurance laws?			-] No []	N/A	[]
11.	What is the name, address and affiliation (officer/employee of the rep firm) of the individual providing the statement of actuarial opinion/cert Gary A. Iannone, Vice President of Actuarial Services of United Healt Asylum Street, Hartford, CT 06103	oorting entity or actuary/consultant associated with an tification? thCare Services Inc., an affiliate of Oxford Health Pla	n actuaria ans (NJ),	l consu	ting 5				
12.1	Does the reporting entity own any securities of a real estate holding c					Yes []	No [Χ]
		estate holding company				0			
	12.12 Number of pa	arcels involved				0			0
12.2	If yes, provide explanation	djusted carrying value				\$			0
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITED What changes have been made during the year in the United States	FIES ONLY:							
13.1	what changes have been made during the year in the officed states		• .						
13.2						Yes [1	No [1
13.3	Have there been any changes made to any of the trust indentures du	ring the year?				Yes [-		
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved] No []	N/A	[]
14.1	Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, what a. Honest and ethical conduct, including the ethical handling of actual relationships;	hich includes the following standards?				Yes [X]	No []
	b. Full, fair, accurate, timely and understandable disclosure in the per c. Compliance with applicable governmental laws, rules and regulation. The prompt internal reporting of violations to an appropriate person	ons;	ity;						
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:								
	Has the code of ethics for senior managers been amended?					Yes []	No [Х]
14.21	If the response to 14.2 is yes, provide information related to amendment								
14.3 14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).	specified officers?				Yes []	No [Х]

thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): Day BOARD OF DIRECTORS Some of Circumstances That Can Trigger the Letter of Credit Amount Amount BOARD OF DIRECTORS Some of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances That Can Trigger the Letter of Credit Amount Person of Circumstances Th		SVO Bank List?	entity the beneficiary of a Letter of Credit that is unrelated to re			Yes	[]	No	[X
BOARD OF DIRECTORS Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors or a subordinate committee thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committee thereof? Has the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Has the reporting entity keep a complete permanent record of the proceedings of its board of directors or hustees of any material interest or affiliation on the part of its officers, directors, trustees or responsible employees that is in conflict or its likely to conflict with the official duale of sub-part of its officers, directors, trustees or responsible employees that is in conflict or its likely to conflict with the official duale of sub-part of its officers, directors, trustees or responsible employees that is in conflict or its likely to conflict with the official duale of sub-part of its officers, directors, trustees or responsible employees that is in conflict or its likely to conflict with the official duale of sub-part of its officers is likely to conflict with the official duale of sub-part of its officers is likely to conflict with the official duals of sub-part of its officers is likely to conflict with the official duals of sub-part of its officers is likely to conflict with the official duals of sub-part of its officers is likely to conflict with the official duals of sub-part of its officers. 20.11 To directors or other officers. 20.12 To directors or other officers. 20.21 To directors or other officers. 20.22 To sub-tholders not officers. 20.22 To sub-tho	·								
BOARD OF DIRECTORS Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes [X] No [Xes [X] No [Yes [X] No [Xes [X] No [Xes [X] No [Xes		American Bankers Association	2		3		4		
BOARD OF DIRECTORS Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors and all subordinate committee thereo? Yes [X] No [No Experience of the reporting entity has been properly entity has been propring entity an established procedure for disclosure to its board of directors and all subordinate committees thereo? Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles) (e.g., Generally Accepted (f.		Number							
Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.11 To directors or other officers. \$ 20.18 To stockholders not officers. \$ 20.18 To stockholders not officers. \$ 20.18 To stockholders not officers. \$ 20.19 To stockholders not officers. \$ 20.21 To directors or other officers. \$ 20.22 To stockholders not officers					······				
Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.11 To directors or other officers. \$ 20.18 To stockholders not officers. \$ 20.18 To stockholders not officers. \$ 20.18 To stockholders not officers. \$ 20.19 To stockholders not officers. \$ 20.21 To directors or other officers. \$ 20.22 To stockholders not officers			ROARD OF	DIRECTOR	9				
Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.12 To stockholders not officers. 20.12 To stockholders not officers. 20.13 Trustees, supreme or grand (Fratemal Only). \$ 20.24 To stockholders not officers. \$ 20.25 To stockholders not off	6 .		or sale of all investments of the reporting entity passed upon e	either by the board o	f directors or a subordinate committee	Yes	[X]	No	ı
part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Yes [x] No [FINANCIAL		Does the reporti	ng entity keep a complete permanent record of the proceeding	gs of its board of dire	ectors and all subordinate committees				
FINANCIAL Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.11 To directors or other officers. \$ 20.12 To stockholders not officers. \$ 20.13 Trustees, supreme or grand (Fratemal Only) \$ 20.21 To directors or other officers. \$ 20.22 To stockholders not officers. \$ 21.22 One not		part of any of its	officers, directors, trustees or responsible employees that is in	n conflict or is likely	to conflict with the official duties of such	Yes	ſΧΊ	No	ſ
Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.12 To stockholders not officers. \$ 20.13 Trustees, supreme or grand (Fraternal Only). \$ Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans): 20.21 To directors or other officers. \$ 20.22 To stockholders not officers. \$ 20.23 To stockholders not officers. \$ 21.24 Other. \$ 21.22 Exprowed from others. \$ 21.23 Leased from others. \$ 21.24 Other. \$ 21.23 Leased from others. \$ 22.22 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses. \$ 22.22 Amount paid as expenses. \$ 22.23 Other amounts governed the stockholders and amounts and whether they are a related party. Yes [] No [) 1 If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT 1 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in		person:				100	. ^ 1	110	
Accounting Principles)?		Has this statem			inciples (e.g. Gaperally Accepted				
20.12 To stockholders not officers\$ 20.13 Trustees, supreme or grand (Fratemal Only) \$ Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans): 20.21 To directors or other officers\$ 20.22 To stockholders not officers\$ 20.23 Trustees, supreme or grand (Fratemal Only) \$ Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [] No [] If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others \$ 21.22 Borrowed from others \$ 21.24 Other \$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? 22.21 Amount paid as losses or risk adjustment \$ Yes [X] No [If answer is yes: 22.23 Other amounts paid as expenses Does the reporting entity report any amounts due from parent included in the Page 2 amount: S Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in		Accounting Prin	ciples)?			Yes	[]	No	[X
20.13 Trustess, supreme or grand (Fraternal Only)	1				20.11 To directors or other officers	.\$			
Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans): 20.21 To directors or other officers\$ 20.22 To stockholders not officers\$ 20.23 Trustees, supreme or grand (Fraternal Only)\$ Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others\$ 21.22 Borrowed from others\$ 21.23 Leased from others\$ 21.24 Other\$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses\$ Does the reporting entity report any amounts due from parent, subsidiaries on Page 2 of this statement? Yes [] No [] If yes, indicate any amounts receivable from parent included in the Page 2 amount: Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in						.\$			
Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans): 20.21 To directors or other officers\$ 20.22 To stockholders not officers\$ 20.23 Trustees, supreme or grand (Fraternal Only)\$ Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [] No [) The poly of the current year: 21.21 Rented from others\$ 21.22 Borrowed from others\$ 21.23 Leased from others\$ 21.24 Other\$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? Yes [] No [) Yes [X] No [] Yes [X] No [] Yes [X] No [] If yes, indicate any amounts any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [] No [) If yes, indicate any amounts receivable from parent included in the Page 2 amount:						e			
policy loans): 20.21 To stockholders not officers\$ 20.22 To stockholders not officers\$ 20.23 Trustees, supreme or grand (Fraternal Only)\$ Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others \$ 21.22 Borrowed from others \$ 21.23 Leased from others \$ 21.24 Other \$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses \$ 22.23 Other amounts paid \$ Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [] No [) If yes, indicate any amounts receivable from parent included in the Page 2 amount: \$ Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in	2	Total amount of	loans outstanding at the end of year (inclusive of Separate Ac	counts, exclusive of	· · · · · · · · · · · · · · · · · · ·				
Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others. 21.22 Borrowed from others. 21.23 Leased from others. 21.24 Other. 5 Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses. 5 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in					20.21 To directors or other officers				
Were any assets reported in this statement? If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others. 21.22 Borrowed from others. 21.23 Leased from others. 21.24 Other. Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses. Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? If yes, indicate any amounts receivable from parent included in the Page 2 amount: Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in					20.23 Trustees, supreme or grand	•			
21.21 Rented from others\$ 21.22 Borrowed from others\$ 21.23 Leased from others\$ 21.24 Other\$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses\$ 22.23 Other amounts paid\$ 22.23 Other amounts paid\$ 22.24 Mount paid as expenses\$ 22.25 Mount paid as expenses\$ 22.26 Mount paid as expenses\$ 22.27 Mount paid as expenses\$ 22.28 Mount paid as expenses\$ 22.29 Mount paid as expenses\$ 22.29 Mount paid as expenses\$ 22.21 Mount paid as expenses\$ 22.22 Mount paid as expenses\$ 22.23 Other amounts paid\$ 25 Mos [] No [) 26 If yes, indicate any amounts receivable from parent included in the Page 2 amount\$ 26 Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? 26 If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. Is the Third-Party Agent a Related Party (Yes/No) INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in	l	Were any assets obligation being	s reported in this statement subject to a contractual obligation reported in the statement?	to transfer to anothe	er party without the liability for such				
21.23 Leased from others \$ 21.24 Other \$ Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? Yes [X] No [22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses \$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 23. Yes [] No [X] No [X] 24. If yes, indicate any amounts receivable from parent included in the Page 2 amount: \$ 25. Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? Yes [] No [X] 25. If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. Is the Third-Party Agent a Related Party (Yes/No)	2				21.21 Rented from others	.\$			
Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments?									
Does this statement include payments for assessments as described in the Annual Statement Instructions other than guaranty fund or guaranty association assessments? If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses\$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 22.24 Million and the part of this statement? Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? If yes, indicate any amounts receivable from parent included in the Page 2 amount: Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in									
guaranty association assessments? Yes [X] No [If answer is yes: 22.21 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses \$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 25.25 Other amounts paid \$ 26.25 Other amounts receivable from parent included in the Page 2 amount: Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in						.\$			
If answer is yes: 22.22 Amount paid as losses or risk adjustment \$ 22.22 Amount paid as expenses \$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 23.25 Other amounts paid \$ 24.25 Other amounts paid \$ 25.26 Other amounts paid \$ 26.27 Other amounts paid \$ 27.27 Other amounts paid \$ 28.28 Other amounts paid \$ 29.29 Other amounts paid \$ 29.29 Other amounts paid \$ 20.29 Other amounts paid \$ 20.20 Other amounts paid \$ 21.20 Other amounts paid \$ 22.21 Other amounts paid \$ 22.22 Other amounts paid \$ 22.22 Other amounts paid \$ 23.20 Other amounts paid \$ 24.20 Other amounts paid \$ 25.20 Other amounts paid \$ 25.20 Other amounts paid \$ 26.20 Other amounts paid \$ 26.20 Other amounts paid \$ 26.20 Other amounts paid \$ 27.20 Other amounts paid \$ 28.20 Other amounts paid \$ 29.20 Other amounts paid \$ 20.20 Other amounts paid \$ 20		duaranty associa	nent include payments for assessments as described in the Ar ation assessments?	inual Statement ins	tructions other than guaranty fund or	Yes	[X 1	No	ſ
22.22 Amount paid as expenses \$ 22.23 Other amounts paid \$ 22.23 Other amounts paid \$ 25.25 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [] No [) If yes, indicate any amounts receivable from parent included in the Page 2 amount: \$ Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? Yes [] No [) If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. Is the	2								
Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement?				22	2.22 Amount paid as expenses	.\$			
If yes, indicate any amounts receivable from parent included in the Page 2 amount: Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days? If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. Is the Third-Party Agent a Related Party (Yes/No) INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in				22	2.23 Other amounts paid	\$			23
Does the insurer utilize third parties to pay agent commissions in which the amounts advanced by the third parties are not settled in full within 90 days?		Does the reporti	ng entity report any amounts due from parent, subsidiaries or	affiliates on Page 2	of this statement?	Yes	[]	No	[X
90 days?	2					. \$			
If the response to 24.1 is yes, identify the third-party that pays the agents and whether they are a related party. Is the Third-Party Agent a Related Party (Yes/No) INVESTMENT Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in						Yes	[]	No	[X
Name of Third-Party Name of Third-Party (Yes/No) INVESTMENT 1 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in	2	,							
INVESTMENT 1 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in				Third-Party Age					
INVESTMENT 1 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in				<u> </u>					
1 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in				•	······				
			INVE	SIMENI					
	1					V	ייז	ŅI.	r

25.02	If no, give full and complete info	ormation, relating thereto						
25.03			program including value for collateral and amount of loaned securities, and native is to reference Note 17 where this information is also provided)					
25.04			mount of collateral for conforming programs as outlined in the Risk-Based Capital	.\$				0
25.05	For the reporting entity's securit	ties lending program, report ar	mount of collateral for other programs.	\$				0
25.06			c securities) and 105% (foreign securities) from the counterparty at the Yes [] No) [] N	/A []	Κ]
25.07	Does the reporting entity non-ac	dmit when the collateral receiv	ved from the counterparty falls below 100%?] No] (] N/	/A []	Κ]
25.08			nding agent utilize the Master Securities lending Agreement (MSLA) to Yes [] No] (] N,	/A []	Κ]
25.09	For the reporting entity's securit	ties lending program state the	amount of the following as of December 31 of the current year:					
	25.092 Total be	ook/adjusted carrying value of	al assets reported on Schedule DL, Parts 1 and 2	\$				0
26.1	control of the reporting entity or	r has the reporting entity sold o	g entity owned at December 31 of the current year not exclusively under the or transferred any assets subject to a put option contract that is currently in 25.03).	Yes	[X] No	[J
26.2	If yes, state the amount thereof	f at December 31 of the curren	26.22 Subject to reverse repurchase agreements 26.23 Subject to dollar repurchase agreements 26.24 Subject to reverse dollar repurchase agreements 26.25 Placed under option agreements 26.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies 26.30 Pledged as collateral - excluding collateral pledged t an FHLB	.\$.\$.\$.\$.\$		287,	,367,	0 0 0 0
			backing funding agreements					
26.3	For category (26.26) provide the	e followina						
26.3	For category (26.26) provide the	e following: 1 e of Restriction	2 Description		3 Amoi			
26.3	Nature	1	2 Description		Amou	unt		
26.3 27.1	Nature	1 e of Restriction	2 Description		Amou	unt		I
	Nature Does the reporting entity have a	1 e of Restriction any hedging transactions repo	2 Description	Yes	Amoi	unt 	[X]	
27.1 27.2	Does the reporting entity have a	1 e of Restriction any hedging transactions repo escription of the hedging progra this statement.	Trted on Schedule DB?	Yes	Amoi	unt 	[X]	
27.1 27.2	Does the reporting entity have a lf yes, has a comprehensive de lf no, attach a description with the control of	any hedging transactions reports this statement. ATERNAL REPORTING ENT	Description rted on Schedule DB?	Yes] No	<u>Amou</u> [) [unt 	[X] /A [X	X]
27.1 27.2 INES 2	Does the reporting entity have a lf yes, has a comprehensive de lf no, attach a description with the comprehensive of the comprehensive	any hedging transactions reports this statement. ATERNAL REPORTING ENT. derivatives to hedge variable does the reporting entity utilized.	Description rted on Schedule DB?	Yes] No Yes Yes Yes	[[[[[unt] No] N	[X] [X] [X] [X] [X]	- X]
27.1 27.2 INES 2 27.3	Nature Does the reporting entity have a If yes, has a comprehensive de If no, attach a description with the T.3 through 27.5: FOR LIFE/FR. Does the reporting entity utilize If the response to 27.3 is YES, By responding YES to 27.41 refollowing: The reporting entity ha Hedging strategy subjetication has reserves and provides Financial Officer Certification	any hedging transactions reports this statement. ATERNAL REPORTING ENTermoly derivatives to hedge variable does the reporting entity utilized as obtained explicit approval from the special accounting process to the special accounting process as obtained explicit approval from the special accounting process as obtained which indicates the impact of the hedging stratication has been obtained which indication has been obtained which in VM-21 and that the Clearly I	Description rted on Schedule DB?	Yes] No Yes Yes Yes Yes	[[[[[] No] No] No] No] No	[X] X] X []	X]
27.1 27.2 INES 2 27.3 27.4	Does the reporting entity have a lifyes, has a comprehensive de lifno, attach a description with the properties of the reporting entity utilize. The response to 27.3 is YES, and the response to 27.3 is YES, and the response to 27.3 is YES, and the response to 27.41 response to 27.4	any hedging transactions reports as secreption of the hedging prograths statement. ATERNAL REPORTING ENT and derivatives to hedge variable does the reporting entity utilized as obtained explicit approval from the special accounting programs been obtained which indicate the impact of the hedging stratication has been obtained which indicate the impact of the hedging stratication has been obtained which indicate the impact of the hedging stratication has been obtained which in VM-21 and that the Clearly I sk mitigation efforts.	Description Tred on Schedule DB?	Yes] No Yes Yes Yes Yes Yes Yes	[] No	[X] A\(\) [] A\(\	- X]
27.1 27.2 INES 2 27.3 27.4	Does the reporting entity have a lifyes, has a comprehensive de lif no, attach a description with the lift of the response to 27.3 is YES, lift the response to 27.3 is YES, lift the response to 27.3 is YES, lift the response to 27.41 refollowing: The reporting entity hae Hedging strategy subjective Actuarial certification hereserves and provides Financial Officer Certification that the lift is actual day-to-day risk were any preferred stocks or be issuer, convertible into equity?	any hedging transactions reports this statement. ATERNAL REPORTING ENTermoly derivatives to hedge variable does the reporting entity utilized as obtained explicit approval freect to the special accounting phas been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging str	Description Tred on Schedule DB?	Yes No Yes Yes Yes Yes Yes Yes	[[[[[[[[[[No No No No No No No No	() A () A	- X]
27.1 27.2 INES 2 27.3 27.4 27.5	Does the reporting entity have a lifyes, has a comprehensive de lif no, attach a description with the lift no not not not not not not not not not	any hedging transactions reports this statement. ATERNAL REPORTING ENTeres derivatives to hedge variable does the reporting entity utilized as obtained explicit approval from the hedging strates of the special accounting phase been obtained which indicate the impact of the hedging strates of the hedging strates of the special accounting the special accounting the special accounting phase been obtained which indicate the impact of the hedging strates of the special accounting phase been obtained which indicates the impact of the hedging strates of the special accounting the special accounti	Description Tried on Schedule DB? Tries ONLY: Tries On	Yes Yes Yes Yes Yes Yes Yes Yes	[[[[[[[[[[[[[[[[[[[No No No No No No No No	() A\()	- X]]] !
27.1 27.2 INES 2 27.3 27.4 27.5	Does the reporting entity have a lifyes, has a comprehensive de lif no, attach a description with the lift of the response to 27.3 is YES, and the response to 27.3 is YES, and the response to 27.3 is YES, and lift of the response to 27.3 is YES, and lift of the response to 27.41 regroups of the reporting entity has been supported by the response to 27.41 regroups of 27.41 reg	any hedging transactions reports this statement. ATERNAL REPORTING ENT derivatives to hedge variable does the reporting entity utilized as obtained explicit approval freet to the special accounting phas been obtained which indicate the impact of the hedging straffication has been obtained which indicate the impact of the hedging straffication has been obtained which indicate the impact of the hedging straffication has been obtained which indicate the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication has been obtained which indicates the impact of the hedging straffication	Description red on Schedule DB?	Yes Yes Yes Yes Yes Yes Yes Yes	[[[[[[[[[[[[[[[[[[[No No No No No No No No	() A\()	- X]]] !
27.1 27.2 INES 2 27.3 27.4 27.5	Does the reporting entity have a lifyes, has a comprehensive de lif no, attach a description with the lift. Through 27.5: FOR LIFE/FR. Does the reporting entity utilize lif the response to 27.3 is YES, By responding YES to 27.41 refollowing: The reporting entity hae Hedging strategy subjee Actuarial certification he reserves and provides. Financial Officer Certification of the lift of	any hedging transactions reports this statement. ATERNAL REPORTING ENT ederivatives to hedge variable does the reporting entity utilized as obtained explicit approval freet to the special accounting phase been obtained which indicate the impact of the hedging stratication has been obtained which indicate the impact of the hedging stratication has been obtained which in VM-21 and that the Clearly lisk mitigation efforts. For at December 31 of the current phase is a proposition of the	Description rted on Schedule DB?	Yes Yes Yes Yes Yes Yes Yes Yes	[[[X	No No No No No No No No	() A\())	- X]]] !

GENERAL INTERROGATORIES

29.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

3					
Name(s)	Name(s) Location(s) Complete Explanation(s)				
	ave there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?				
1	2	3	4		
Old Custodian	New Custodian Date	of Change	Passon		

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
DWS Investment Management Americas Inc.	U
BlackRock Financial Management, Inc	U
Internally Managed	I
,	

designated with a "U") manage more than 10% of the reporting entity's invested assets?	Yes [X]	No [
29.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?	Yes [X]	No [

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
104518	DWS Investment Management Americas Inc.	CZ83K4EEEX8QVCT3B128	SEC	NO
107105	BlackRock Financial Management, Inc	549300LVXY1VJKE13M84	SEC	NO

30.1	Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and			
	Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])?	Yes [] [No [X]
30.2	If wes, complete the following schedule:			

30.2 If yes, complete the following schedule:

29.03 29.04

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	278,827,077	277,251,074	(1,576,003)
31.2 Preferred stocks	0	0	0
31.3 Totals	278,827,077	277,251,074	(1,576,003)

 Describe the sources or methods utilized in determining the fair values: For those securities that had prices in the NAIC SVO ISIS database, those prices were used; for those securities that did not have the NAIC SVO ISIS database, pricing was obtained from Hub which is an external data sources vendor. Hub utilizes various pricin Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D? If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronall brokers or custodians used as a pricing source? If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosurable for Schedule D: 	onic copy) for			No [X]
 32.2 If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electron all brokers or custodians used as a pricing source? 32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure. 	onic copy) for			
all brokers or custodians used as a pricing source? 32.3 If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosu	ure of fair	Yes []	No []
 Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? If no, list exceptions: N/A 		Yes [)	(]	No []
 By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FI security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities? 		Yes []	No [X]
 By self-designating PLGI securities, the reporting entity is certifying its compliance with the requirements as specified in the Purpo Procedures Manual of the NAIC Investment Analysis Office (P&P Manual) for private letter rating (PLR) securities and the following of each self-designated PLGI security: a. The security was either: i. issued prior to January 1, 2018 (which is exempt from PLR filing requirements pursuant to the P&P Manual), or ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1 which confidentiality agreement remains in force, for which an insurance company cannot provide a copy of a private letter rationale report to the SVO due to confidentiality or other contractual reasons ("waived submission PLR securities"). b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for security. c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its I capacity as a NRSRO which is shown on a current private letter rating, dated during the financial statement year, held by the and available for examination by state insurance regulators. d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued of January 1, 2022, if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale for PL security with the SVO, it certifies that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation. 	1, 2022 In rating or the legal e insurer on or after eport of the			
 Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified in the P&P M 36. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSI January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? 	RO prior to			No [X]
 By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Par (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the trans which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria? 	d at the saction for a in 37.a -] No []	N/A [X]

38.1	Does the reporting entity directly hold cryptocurrencies?		Yes [] No	o [X]
38.2	If the response to 38.1 is yes, on what schedule are they reported?				
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premiums on policies?		Yes [] No) [X]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately converted to U.S. dollars? 39.21 Held directly] No) []) []
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiums or that are held directly.				
	1 2 Immediately Converted to USD, Name of Cryptocurrency Directly Held, or Both	3 Accepted for Payment of Premiums			
	OTHER				
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to service organizations, and statistical or rating bureaus during the period covered by this statement. 1 2 Name Amount Pa	trade associatio			0
41.1	Amount of payments for legal expenses, if any?		\$		0
41.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal enduring the period covered by this statement.	rpenses			
	1 2 Name Amount Pa	id			
42.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers, or departments of governments of governments.	nent, if any?	\$		0
42.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditure connection with matters before legislative bodies, officers, or departments of government during the period covered by this state.				
	1 2 Name Amount Pa	id			

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in force?	
1.2	If yes, indicate premium earned on U.S. business only.	
1.3	What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit?	\$0
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above	
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.	\$0
1.6	Individual policies: Most current three years:	
	1.61 Total premium earned	
	1.62 Total incurred claims	\$0
	1.63 Number of covered lives	0
	All years prior to most current three years:	
	1.64 Total premium earned	
	1.65 Total incurred claims	
	1.66 Number of covered lives	
	inde National Control and Cont	
1.7	Group policies: Most current three years:	
1.7	1.71 Total premium earned	¢ 0
	1.72 Total incurred claims	
	1.73 Number of covered lives	
	All years prior to most current three years:	
	1.74 Total premium earned	
	1.75 Total incurred claims	\$0
	1.76 Number of covered lives	0
2.	Health Test:	
	1 2	
	Current Year Prior Year	
	2.1 Premium Numerator	
	2.2 Premium Denominator	
	2.3 Premium Ratio (2.1/2.2)	
	2.4 Reserve Numerator	
	2.5 Reserve Denominator	
	2.6 Reserve Ratio (2.4/2.5)	
3.1	Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be	
	returned when, as and if the earnings of the reporting entity permits?	Yes [] No [X]
3.2	If yes, give particulars:	
4.1	Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and	Yes [X] No []
	dependents been filed with the appropriate regulatory agency?	
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered?	Yes [] No []
5.1	Does the reporting entity have stop-loss reinsurance?	Yes [] No [X]
5.2	If no, explain: Oxford Health Plans (NJ), Inc. is not required to have stop loss reinsurance	
5.3	Maximum retained risk (see instructions) 5.31 Comprehensive Medical	
	5.32 Medical Only	\$0
	5.33 Medicare Supplement	
	5.34 Dental & Vision	
	5.35 Other Limited Benefit Plan	
	5.36 Other	s 0
	5.50 Other	ψ
6.	Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:	
	Hold harmless clauses in provider agreements.	
7.1	Does the reporting entity set up its claim liability for provider services on a service date basis?	Yes [X] No []
7.2	If no, give details	
8.	Provide the following information regarding participating providers: 8.1 Number of providers at start of reporting year	
0.1	8.2 Number of providers at end of reporting year	
9.1	Does the reporting entity have business subject to premium rate guarantees?	res[]NO[X]
9.2	If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months	s \$ 0
5.∠	If yes, direct premium earned: 9.21 Business with rate guarantees between 15-36 months 9.22 Business with rate guarantees over 36 months	

10.1	Does the reporting entity have Incentive Pool, Withh	nold or Bonus Arı	rangements in its p	rovider contracts	?		Yes [X] No	[]
10.2	If yes:		10).21 Maximum am	nount payable bonus	ses	\$	7.	587.426
	, 555.				ally paid for year bo				
					ount payable withh				
			10	0.24 Amount actua	ally paid for year wit	hholds	\$	2,	291,372
11.1	Is the reporting entity organized as:								
	3 · · · · · · · · · · · · · · · · · · ·			11.12 A Medic	al Group/Staff Mode	el,	Yes [] No	[X]
					idual Practice Assoc	, ,,	Yes [[X]
				11.14 A Mixed	Model (combination	of above)?	Yes [] No	[X]
11.2	Is the reporting entity subject to Statutory Minimum	Capital and Surn	lus Requirements	,			Yes [X	1 No	[]
11.3	If yes, show the name of the state requiring such mi						_		Jersey
11.4	If yes, show the amount required								987,403
11.5	Is this amount included as part of a contingency res	erve in stockhold	ler's equity?				Yes [] No	[X]
11.6	If the amount is calculated, show the calculation 100% of the sum of \$59,759,034 (8% fee for service	e and hospital no	n contracted costs) and \$13.228.369	9 (4% of contracted	hospital costs)			
	(**************************************			, , -, -,	(, , , , , , , , , , , , , , , , , , , ,			
12.	List service areas in which reporting entity is license	ed to operate:							
			1 Name of Service	Area					
	Kent, DE								
		,							
			 }						
		•							
		* '	ies						
	,								
	· · · ·								
13.1	Do you act as a custodian for health savings accour	nts?					Yes [] No	[X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$		0
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No	[X]
13.4	If yes, please provide the balance of funds administration	ered as of the rep	porting date				\$		0
14.1	Are any of the captive affiliates reported on Schedul	e S. Part 3. auth	orized reinsurers?			Yes [l No f	1 N	/A [X]
	If the answer to 14.1 is yes, please provide the follow						1 [,	,[]
	1	2	3	4	Assets	Supporting Reserve	e Credit		
		NAIC Company	Domiciliary	Reserve	5 Letters of	6 Trust	7		
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Othe	er	
15.	Provide the following for individual ordinary life insur	rance* nolicies (l	IS husiness only	for the current ve	ar (prior to reinsura	nce assumed or			
10.	ceded):	ance policies (c	o.o. business only	ioi uic carrent ye	ar (prior to remoura	nec assumed of			
					Direct Premium Wri				
					Total Incurred Claim Number of Covered				
				10.01	tamber of covered				
	Taras (b. ath as falla		nary Life Insurance		!!\				
	Term(whether full und Whole Life (whether								
	Variable Life (with or	without seconda	ry gurarantee)	.,,	FF /				
	Universal Life (with o Variable Universal Li			intee)					
	- and so chiveled Er		guidit	/					
16.	Is the reporting entity licensed or chartered, register	ed, qualified, elig	ible or writing busi	ness in at least tw	o states?		Yes [X]	No []
16.1	If no, does the reporting entity assume reinsurance								
	domicile of the reporting entity?						Yes []	No [1

FIVE-YEAR HISTORICAL DATA

		1 2024	2 2023	3 2022	4 2021	5 2020
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	525.094.890	562 .722 .837	367.734.397	355.331.482	293.828.989
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement					
4.	Total capital and surplus (Page 3, Line 33)					
٦.	Income Statement (Page 4)				200,070, 101	
5.	Total revenues (Line 8)	2 006 195 928	2 033 133 154	1 536 048 694	1 221 862 548	991 799 185
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
12.	Cash Flow (Page 6)	00, 101,770	120,000,077	120,070,002	101,714,002	
13.	Net cash from operations (Line 11)	53 035 100	142 490 674	157 182 824	87 631 0 77	70 760 016
13.	Risk-Based Capital Analysis	30,000, 100	142,400,074	107, 102,024		70,700,010
14.	Total adjusted capital	361 050 345	352 544 318	227 /18 300	223 575 151	210 222 071
15.	Authorized control level risk-based capital					
13.	Enrollment (Exhibit 1)	33,000,311	31,073,113		32,432,001	23,702,004
16.	Total members at end of period (Column 5, Line 7)	84 884	97 094	76 546	62 565	5/ 362
	Total members at end of period (Column 5, Line 7) Total members months (Column 6, Line 7)					
17.	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	1,007,073	1,094,402			
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	86.7	83.2	79.8	79.6	75.9
20.	Cost containment expenses	2.3	2.1	2.1	2.6	2.8
21.	Other claims adjustment expenses	0.6	0.7	0.6	0.7	0.9
22.	Total underwriting deductions (Line 23)	95.9	92.9	89.9	89.6	88.4
23.	Total underwriting gain (loss) (Line 24)	4.1	7.1	10.1	10.4	11.6
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	40,822,345	211,587	(201,378)	11,159,076	11,571,889
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	50,033,404	(3,574,940)	2,988,605	12,942,826	22,887,608
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)					
30.	Affiliated mortgage loans on real estate				0	
31.	All other affiliated				0	0
32.	Total of above Lines 26 to 31				0	0
33.	Total investment in parent included in Lines 26 to					
	31 above. If a party to a merger, have the two most recent years of	0	0	0	0	0

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS **Allocated by States and Territories** 10 Federal Employees Health Annuity Active Accident and Benefits Premiums & Property/ Total Deposit-Type Contracts Health Medicaid CHIP Title Program Other Columns 2 States, etc. Premiums Title XVIII Premiums Through 8 (a) 1 Alabama ΑI N n n 0 n n n n n 0 2. Alaska . ΑK .N. .0 .0 .0 .0 .0 . 0 .0 0 .0 3. Arizona. ΑZ N. .0 .0 .0 . 0 .0 . 0 .0 0 .0 4. Arkansas .. AR .0 .N. .0 .0 .0 .0 .0 .0 .0 .0 5. California CA .0 .0 .0 .0 .0 .0 .0 .0 0 .N. Colorado .0 .0 СО 0 0 7. Connecticut СТ .0 . 0 .0 . 0 .0 . 0 .0 0 .0 .N. 8. Delaware DE n 158,003,169 0 n 0 n n 158,003,169 .0 9. District of Columbia DC N 0 0 0 0 0 0 0 0 0 10. Florida. FL .N. .0 .0 .0 .0 .0 .0 .0 .0 .0 11. Georgia GΑ .N. .0 .0 .0 .0 .0 .0 .0 .0 .0 12. Hawaii0 .0 .0 .0 .0 . 0 .0 0 .0 ΗΙ 13. Idaho .0 .0 14. Illinois 0 0 0 n 0 0 0 0 .0 15 Indiana INI N ٥ ٥ Λ ٥ ٥ ٥ ٥ n Λ 16. lowa .. IΑ N. .0 .0 .0 .0 .0 . 0 .0 . 0 .0 17. Kansas KS N. .0 .0 .0 .0 .0 . 0 .0 . 0 .0 18. Kentucky .. ΚY .N. .0 .0 .0 .0 .0 .0 .0 .0 .0 19. Louisiana .0 .0 .0 .0 .0 .0 .0 .0 .0 LA 20. Maine .. .0 .0 21 Maryland . MD .0 . 0 .0 0 .0 . 0 .0 0 .0 22 Massachusetts MA .N. n n 0 0 0 n n n 0 23 Michigan MI N 0 n n 0 0 n 0 n n 24. Minnesota MN .N. .0 .0 .0 .0 .0 .0 .0 .0 .0 Mississippi 25. MS .0 .N. .0 .0 .0 .0 .0 .0 .0 .0 26 МО .0 .0 .0 .0 .0 .0 27. Montana МТ .0 0 0 28 Nebraska .0 .0 .0 n .0 . 0 n n .0 NE 29. Nevada . NV N 0 0 0 0 0 0 0 0 0 30. New Hampshire NH N 0 0 0 0 0 0 0 0 0 758,051 986,364,448 .987,122,499 31. New Jersey NJ .L.. .0 .0 .0 .0 .0 .0 New Mexico 32. .N. .0 .0 .0 .0 .0 .0 .0 .0 NM .0 33. New York ... NY .0 .0 .0 .0 .0 .0 .0 .0 .0 .N. 34. North Carolina0 .N .0 .0 .0 .0 .0 35 North Dakota ND 0 .0 .0 0 .0 0 0 0 .0 36 Ohio ОН N n n 0 n 0 n n n 0 37. Oklahoma ΟK N. .0 .0 .0 .0 .0 . 0 .0 . 0 .0 38. Oregon OR L. .0 11.430.855 .0 .0 .0 . 0 .0 11.430.855 .0 .611,510,146 .611,510,146 39. Pennsylvania PA .0 .0 .0 .0 .0 .0 .0 40. Rhode Island RI .0 .229,243,784 .0 .0 .0 .0 .0 .229,243,784 .0 41. South Carolina0 SC .N .0 .0 0 42. South Dakota0 . 0 .0 . 0 .0 . 0 .0 0 .0 SD Tennessee 43. ΤN .N. n 0 0 n 0 n n n .0 44. Texas ΤX N 0 0 0 0 0 0 0 0 0 45. Utah .. UT .N. .0 .0 .0 .0 .0 .0 .0 .0 .0 46. VT Vermont0 .0 .0 .0 .0 .0 .0 .0 .0 .N. 47 Virginia0 .0 .0 .0 .0 . 0 .0 0 .0 VA Washington 48. .0 .0 49 West Virginia WV 0 0 0 n 0 0 0 0 .0 Wisconsin 50 ١//١ N ٥ ٥ Λ ٥ ٥ ٥ ٥ n Λ 51. Wyoming WY N. .0 .0 .0 .0 .0 . 0 .0 . 0 .0 52. American Samoa AS .N... .0 .0 .0 .0 .0 . 0 .0 . 0 .0 53. Guam . GU .0 .N. .0 .0 .0 .0 .0 .0 .0 .0 54 Puerto Rico0 .0 .0 .0 .0 .0 .0 .0 .0 PR .N... U.S. Virgin Islands .. 55. 56. Northern Mariana Islands Canada 57. .0 .0 .0 .N. .0 .0 .0 .0 .0 0 58. Aggregate Other XXX. 0 0 0 Aliens .. 59 Subtotal 758,051 ,996,552,402 .0 .0 .0 .0 ,997,310,453 .0 XXX .0 60 Reporting Entity Contributions for Employee XXX. .0 .0 .0 .0 .0 Benefit Plans Totals (Direct Business) 1,996,552,402 ,997,310,453 61 758,051 0 0 0 0 0 XXX DETAILS OF WRITE-INS 58001 XXX 58002. XXX. 58003 XXX. Summary of remaining write-ins for Line 58 from 58998

ab<u>ove)</u> 0 0 0 0 (a) Active Status Counts: 1. L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG. 6 4. Q - Qualified - Qualified or accredited reinsurer. 2. R - Registered - Non-domiciled RRGs.. 5. N - None of the above - Not allowed to write business in the state..... 510

.0

.0

.0

.0

.0

0

.0

.0


XXX.


overflow page Totals (Lines 58001 through


58003 plus 58998)(Line 58


58999


^{3.} E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0 (b) Explanation of basis of allocation by states, premiums by state, etc. Premiums are allocated by state based on geographic market.













































PART 1 - ORGANIZATIONAL CHART





40.15













































































Continued from Previous Page


SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 - ORGANIZATIONAL CHART

Surgical Care Affiliates, LLC

20-8922307 100%

Substantively Controlled Surgical Care Affiliate Entities



PART 1 - ORGANIZATIONAL CHART

		Beneficially Owned Legal Entities				
Entity Name	Juris.	Federal Tax ID	Entity Name	Juris.	Federal Tax ID	
4C Medical Group, PLC	AZ	45-2402948	Christopher Stalberg, M.D., PLLC	AZ	26-4651320	
A.G. Dikengil, Inc.	NJ	22-3149900	Cielo House, Inc.	CA	27-1655973	
AbleTo Behavioral Health Services of Michigan, P.C.	MI	85-4328419	Cognitive-Behavioral Therapy Center of Western North Carolina, P.A.	NC	20-3056794	
AbleTo Behavioral Health Services of New Jersey, P.C.	NJ	85-4306375	Colonial Family Practice, L.L.C.	SC	02-0626080	
AbleTo Behavioral Health Services, PC	CT	47-5519672	Columbia Counseling Center P.A.	MD	52-2052733	
AbleTo Licensed Clinical Social Worker Services, P.C.	CA	85-0739865	Connect Medical, P.C.	NY	32-0551188	
AbleTo Psychiatry Health Services, P.C.	MA	88-2290313	Crystal Run Healthcare Physicians LLP	NY	13-3843560	
AHN Accountable Care Organization, LLC	IN	45-4171713	David C. Anderholm, M.D., P.A.	MN	41-1879063	
AHN Surgery Center Holdings, LLC	IN	82-5224188	David Moen, M.D. P.C.	NY	81-5101448	
Aleph Psychological Services, Inc.	CA	46-3477124	David R. Ferrell, M.D., P.C.	NV	45-2380022	
Ambulatory Partner Holdings, LLC	NY	88-2464526	DBT and EMDR Specialists, P.A.	MN	47-3322541	
American Health Network of Indiana, LLC	IN	35-2108729	Digestive Diseases Diagnostic & Treatment Center, LLC	NY	26-1319443	
Angie Coil FNP, PLLC	AZ	81-2112951	Doc Martins, PLLC	AZ	20-0419099	
AppleCare Hospitalists Medical Group, Inc.	CA	14-1890491	Durable Medical Equipment, Inc.	MA	04-3106404	
AppleCare Medical Group St. Francis, Inc.	CA	33-0845269	East Side Endoscopy, L.L.C.	NY	91-1665997	
AppleCare Medical Group, Inc.	CA	33-0898174	Elite Focus Clinic, Inc., a Professional Corporation	CA	47-3861802	
ARTA Western California, Inc.	CA	33-0658815	Empire Physicians' Medical Group, Inc.	CA	33-0181426	
Astra Medical Clinic, PLLC	AZ	86-0882561	Endoscopy Center of Western New York, L.L.C.	NY	36-4427974	
Atrius Health Ambulatory Surgery Center, LLC	MA		Eugene Center for Anxiety and Stress, LLC	OR	83-2740282	
Atrius Health, Inc.	MA	04-3397450	Eugene Therapy, LLC	OR	90-0624377	
Beaver Medical Group, P.C.	CA	33-0645967	Everett Physicians, Inc. P.S.	WA	81-1625636	
Behavioral Solutions, P.C.	MA	04-3316367	Evolve, LLC	WI	61-1752488	
Bexar Imaging Center, LLC	TX	22-3858211	Family Counseling Associates of Salem Andover LLC	NH	27-0820363	
California Spring Holdings, PC	CA	81-0881243	Ferrell Physician Services, P.C.	NY	87-4007730	
Carbondale Counseling Associates, PLLC	IL	47-1130641	First Step Services, PLLC	NC	51-0484581	
Cardiothoracic & Vascular Surgical Associates, P.A.	FL	59-3338654	Five Rivers South L.L.C.	MN	92-0459013	
CARE Clinics LLC	MN	46-4814778	Flagstaff Family Physicians, PLLC	AZ	86-0959327	
CARE Free Counseling LLC	MN	88-0822778	Good Samaritan Medical Practice Association, Inc., A Medical Group	CA	95-3969271	
CareMount Health Solutions ACO, LLC	NY	n/a	Great South Bay Endoscopy Center, LLC	NY	46-3055867	
Carnegie Hill Endoscopy, LLC	NY	27-0385539	Greater Phoenix Collaborative Care, P.C.	AZ	27-2337725	
Carolina Behavioral Care, P.A.	NC	56-1780933	Gunn Behavioral Care of California, P.C.	CA	27-3237563	
Carroll Counseling Center LLC	MD	52-2072546	Gunn Behavioral Holdco, P.C.	CA	92-3292446	
Centers for Family Medicine, GP	CA	33-0483510	HealthCare Partners Affiliates Medical Group	CA	95-4526112	

PART 1 - ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID	Entity Name	Juris.	Federal Tax ID
HealthCare Partners ASC-HB, LLC	CA	26-4247365	Landmark Medical of Ohio, Professional Corporation	ОН	82-4864947
HealthCare Partners Associates Medical Group, P.C.	CA	45-5273760	Landmark Medical of Oregon, P.C.	OR	47-2926188
HealthCare Partners Medical Group, P.C.	CA	95-4340584	Landmark Medical of Pennsylvania, PC	PA	81-1605378
Heron Ridge Assoc., P.L.C.	MI	80-0020865	Landmark Medical of Rhode Island, PC	RI	84-2830065
Homecare Dimensions of Florida, Inc.	TX	81-0884465	Landmark Medical of Tennessee, PC	TN	30-1288593
Homecare Dimensions, Inc.	TX	74-2758644	Landmark Medical of Texas, PA	TX	83-2296389
IN Style OPTICAL, LLC	MA	27-3296953	Landmark Medical of Utah, PC	UT	84-2660339
Inland Faculty Medical Group, Inc.	CA	33-0618077	Landmark Medical of Virginia, P.C.	VA	85-0839774
Inspiris Medical Services of New Jersey, P.C.	NJ	45-2563134	Landmark Medical of Washington, PC	WA	47-3028655
INSPIRIS of Michigan Medical Services, P.C.	MI	27-1561674	Landmark Medical, P.C.	NY	47-1588943
INSPIRIS of New York Medical Services, P.C.	NY	13-4168739	Level2 Medical Services, P.A.	DE	84-5003916
INSPIRIS of Pennsylvania Medical Services, P.C.	PA	26-2895670	Level2 Medical Services, P.A. New Jersey	NJ	87-2684015
Jonathan E. Goldberg, Ph.D., Inc.	MA	26-3013277	Level2 Medical Services, P.C. Alaska	AK	87-2600511
Joyce Marter & Associates, P.C.	IL	26-3478896	Level2 Medical Services, P.C. California	CA	92-1153396
K.P. Counseling, Ltd.	IL	30-0089259	Level2 Medical Services, P.C. Utah	UT	87-0989804
Kelsey-Seybold Medical Group, PLLC	TX	76-0386391	Liberty Endoscopy Center, LLC	NY	46-4588779
Keys Counseling, Inc.	IN	30-0358493	Life Strategies Counseling, Inc.	AR	20-0468524
KS Pharm, LLC	TX	84-2355006	LifeSolutions Counseling Associates, P.C.	IN	26-3292877
KS SC, LLC	TX	84-2241460	Long Island Digestive Endoscopy Center, LLC	NY	45-4714972
Landmark Medical of Arkansas, P.A.	AR	85-0997438	Manhattan Endoscopy Center, LLC	NY	27-1510596
Landmark Medical of California, PC	CA	47-4553619	March Vision Care Group, Incorporated	CA	95-4874334
Landmark Medical of Connecticut, PC	CT	83-2295301	March Vision Care IPA, Inc.	NY	27-3115058
Landmark Medical of Florida, P.A.	FL	85-0838149	March Vision Care of Texas, Inc.	TX	45-4227915
Landmark Medical of Idaho, PC	ID	92-0496439	MAT-RX DEVELOPMENT, L.L.C.	TX	43-1967820
Landmark Medical of Kansas, P.A.	KS	82-4633545	Mat-Rx Fort Worth GP, L.L.C.	TX	35-2262695
Landmark Medical of Kentucky, P.S.C.	KY	82-4881602	ME Urgent Care Nebraska, Inc.	NE	81-0936574
Landmark Medical of Louisiana, a Professional Corporation	LA	82-4881732	MedExpress Employed Services, Inc.	DE	81-1265129
Landmark Medical of Massachusetts, PLLC	MA	81-5364097	MedExpress Primary Care Arizona, P.C.	AZ	81-4550969
Landmark Medical of Michigan, P.C.	MI	86-3599871	MedExpress Primary Care Arkansas, P.A.	AR	84-4234388
Landmark Medical of Mississippi, P.C.	MS	82-5084178	MedExpress Primary Care Kansas, P.A.	KS	81-4605885
Landmark Medical of Missouri, P.C.	МО	82-4857713	MedExpress Primary Care Maryland, P.C.	MD	82-3384324
Landmark Medical of New Hampshire, P.C.	NH	85-1174070	MedExpress Primary Care Massachusetts, P.C.	MA	82-1096099
Landmark Medical of North Carolina, P.C.	NC	82-4256752	MedExpress Primary Care Minnesota P.C.	MN	81-4396738

PART 1 - ORGANIZATIONAL CHART

		Beneficially Owned Legal Entitles			
Entity Name	Juris.	Federal Tax ID	Entity Name	Juris.	Federal Tax ID
MedExpress Primary Care Oklahoma, P.C.	ОК	83-1077265	MedExpress, Inc. – Delaw are	DE	45-5436856
MedExpress Primary Care South Carolina, P.C.	SC	83-0764858	Mental Health Resources, PLLC	TN	62-1396317
MedExpress Primary Care Texas, P.A.	TX	84-2500750	MH Physician Three Holdco, a Medical Corporation	CA	27-4691544
MedExpress Primary Care Virginia, P.C.	VA	82-3395792	MHCH, Inc.	CA	80-0507474
MedExpress Primary Care West Virginia, Inc.	WV	82-4401181	MHIPA Physician Tw o Holdco, a Medical Corporation	CA	27-4691508
MedExpress Primary Care Wisconsin, S.C.	WI	81-4563448	Midtow n Medical, L.P.	CA	83-2873776
MedExpress Urgent Care – New Jersey, P.C.	NJ	45-5388778	Mindscapes Counseling, PLLC	CT	47-2117693
MedExpress Urgent Care - Northern New Jersey PC	NJ	83-2089623	Mobile Medical Services of New Jersey, PC	NJ	81-2977678
MedExpress Urgent Care Arizona, P.C.	AZ	81-4030280	Mobile Medical Services, P.C.	NY	30-0445773
MedExpress Urgent Care Arkansas, P.A.	AR	46-4348120	Monarch Health Plan, Inc.	CA	22-3935634
MedExpress Urgent Care California, P.C.	CA	82-0930142	Monarch HealthCare, A Medical Group, Inc.	CA	33-0587660
MedExpress Urgent Care Connecticut, P.C.	CT	81-1956812	NAMM Medical Group Holdings, Inc.	CA	56-2627070
MedExpress Urgent Care Idaho, P.C.	ID	82-1135336	NC Center For Resiliency, PLLC	NC	47-2693055
MedExpress Urgent Care Illinois, P.C.	IL	47-4308614	New Perspectives Center for Counseling & Therapy, L.L.C.	OR	93-1173779
MedExpress Urgent Care low a, P.C.	IA	81-5353472	New York Licensed Clinical Social Work, P.C.	NY	86-3891057
MedExpress Urgent Care Kansas, P.A.	KS	47-1919283	Northern California Physicians Network, Inc., a Professional Corporation	CA	81-1573604
MedExpress Urgent Care Minnesota P.C.	MN	81-1125396	Northlight Counseling Associates, Inc.	AZ	86-0646417
MedExpress Urgent Care Missouri P.C.	MO	47-3132625	Northw est Medical Group Alliance, LLC	WA	91-1699944
MedExpress Urgent Care North Carolina, P.C.	NC	81-5138747	NPN IPA Washington, PLLC	WA	61-1855159
MedExpress Urgent Care Oregon, P.C.	OR	82-1919436	Oakland Psychological Clinic, P.C.	MI	38-2481929
MedExpress Urgent Care Rhode Island, P.C.	RI	81-5362765	OHR Physician Group, P.C.	OR	93-0979031
MedExpress Urgent Care South Carolina, P.C.	SC	81-5380706	Optum Behavioral Care of California, P.C.	CA	84-4887072
MedExpress Urgent Care Texas, P.A.	TX	47-5147441	Optum Behavioral Care of Colorado, P.C.	CO	93-2952612
MedExpress Urgent Care Washington, P.C.	WA	82-2443118	Optum Behavioral Care of Connecticut, P.C.	CT	93-2339326
MedExpress Urgent Care Wisconsin, S.C.	WI	81-4281678	Optum Behavioral Care of Kansas, P.A.	KS	93-3404672
MedExpress Urgent Care, P.C. – Georgia	GA	47-1804667	Optum Behavioral Care of New Jersey, P.C.	NJ	85-0666386
MedExpress Urgent Care, P.C. – Indiana	IN	90-0929572	Optum Behavioral Care of North Carolina, P.C.	NC	85-1959641
MedExpress Urgent Care, P.C. – Maryland	MD	45-3461101	Optum Behavioral Care of Texas, P.A.	TX	84-3152209
MedExpress Urgent Care, P.C. – Massachusetts	MA	47-1857908	Optum Behavioral Care Therapy Services of Illinois, P.C.	IL	99-4597708
MedExpress Urgent Care, P.C. – Michigan	MI	46-4793937	Optum Care Washington, PLLC	WA	91-0214500
MedExpress Urgent Care, P.C. – Oklahoma	OK	47-1824365	Optum Clinic, P.A.	TX	75-2778455
MedExpress Urgent Care, P.C. – Tennessee	TN	45-4973138	Optum Everycare, P.C.	PR	66-1026448
MedExpress Urgent Care, P.S.C Kentucky	KY	83-1565124	Optum Medical Care of New Jersey, P.C.	NJ	

Entity Name	Juris.	Beneficially Owner	d Legal Entities Entity Name	Juris.	Federal Tax ID
Optum Medical Care, P.C.	NY	13-3544120	Prospero Medical Services New Jersey, P.C.	NJ	84-3844362
Optum Medical Group (Rhodes), P.C.	NV	88-0310956	Prospero Medical Services, P.A.	FL	87-2406404
Optum Medical Group II (Rhodes), P.C.	NV	86-0857176	Psychiatry Services of New York, P.C.	NY	85-0921665
Optum Medical Group, P.A.	KS	46-2662506	Psychiatry Specialists, S.C.	IL	27-3409538
Optum Medical Services of California, P.C.	CA	30-0826311	Psychological Healthcare, PLLC	NY	16-1484552
Optum Medical Services of Colorado, P.C.	CO	45-5424191	Queens Endoscopy ASC, LLC	NY	27-4189294
Optum Medical Services, P.C.	NC	45-3866363	Red Oak Counseling, Ltd.	WI	20-0785644
Optum Urgent Care, PLLC	NY	46-1883579	Redlands Family Practice Medical Group, Inc.	CA	56-2627067
OptumCare Portland, LLC	OR	93-1306308	Refresh Canopy Cove, Inc.	FL	82-3603285
Oregon Healthcare Resources, LLC	OR	27-3674492	Refresh Connecticut, PLLC	CT	84-2663780
Ortho Physician Partners, P.C.	WA	93-3367856	Refresh Evolve, LLC	WI	83-4507157
OW Physician Partners, P.C.	CA	85-4386308	Refresh In-Home Counseling LLC	IL	82-5351068
Pacific Cardiovascular Associates Medical Group, Inc.	CA	33-0704734	Refresh Pennsylvania, LLC	PA	84-1756547
PE Healthcare Associates, LLC	NY	27-4496894	Reliant Medical Group The Endoscopy Center, LLC	MA	20-5251393
Peninsula Psychological Center, Inc., P.S.	WA	91-1885912	Reliant Medical Group, Inc.	MA	04-2472266
Perspectives of Troy, P.C.	MI	38-2592367	RICBT, Inc.	RI	33-0999953
Physician United PLLC	AZ	84-3476733	Riverside Community Healthplan Medical Group, Inc.	CA	33-0055097
Physicians Medical Group of San Jose, Inc.	CA	94-2722082	Riverside Electronic Healthcare Resources, Inc.	CA	20-3420379
Physicians Medical Holdings	CA	86-2631012	Saad A. Shakir, M.D., Inc.	CA	77-0398259
Pilot Holdings, P.C.	CA	87-3931756	Saddleback Medical Group, Inc.	CA	33-0571462
Pinnacle Medical Group, Inc.	CA	33-0795271	San Bernardino Medical Group, Inc.	CA	95-3088615
Polyclinic Holdings, P.C.	WA	83-3042027	San Diego Physicians Medical Group, Inc.	CA	33-0457134
POLYCLINIC MANAGEMENT SERVICES COMPANY, LLC	WA	46-0508606	Sanvello Behavioral Health Services, P.A.	DE	84-1754732
Primary Care Associated Medical Group, Inc.	CA	33-0527335	Saris Counseling, LLC	WI	n/a
ProHEALTH Care Associates of New Jersey LLP	NJ	47-5656253	Seattle Psychology, P.L.L.C.	WA	46-3238571
ProHEALTH Care Associates, L.L.P.	NY	11-3355604	Sequoia Physician Holdings, P.C.	CA	99-2070439
ProHEALTH Medical NY, P.C.	NY	47-1388406	Serenity Family and Psychological Counseling Center, P.C.	CA	45-3802527
ProHealth Physicians, P.C.	CT	06-1469068	Shark Holdings, P.C.	CA	87-3142148
ProHEALTH Urgent Care Medicine of New Jersey LLP	NJ	47-5661535	Sherman Counseling Management, S.C.	WI	47-5082677
Prospero Health Partners Florida, Inc.	FL	85-0775386	Silicon Valley TMS of Monterey Bay, GP	CA	81-3200297
Prospero Health Partners New York, P.C.	NY	82-2400620	Southw est Internal Medicine Group, Roberto Ruiz, M.D., PLLC	AZ	86-0516447
Prospero Health Partners North Carolina, P.C.	NC	84-4569314	Spring Behavioral Health of New Jersey, LLC	NJ	82-3087236
Prospero Health Partners, P.C.	MN	84-3234753	Springfield Psychological, P.C.	PA	23-2833266

PART 1 - ORGANIZATIONAL CHART

Entity Name	Juris.	Federal Tax ID
St. Vincent IPA Medical, L.P.	CA	95-4729595
Surgical Eye Experts, LLC	MA	65-1321064
Surprise Health Center, PLLC	AZ	86-1047772
Susan Albright P.L.C.	AZ	20-5176158
Talbert Medical Group, P.C.	CA	93-1172065
The Corvallis Clinic, P.C.	OR	93-1221257
The Polyclinic, PLLC	WA	91-0369070
The Potter's House Family & Children Treatment Center, LLC	GA	20-8357849
The Salveo Center, PLLC	WA	80-0281838
The Tabor Therapy Group, Inc.	IL	46-5461304
Triangle Counseling Agency, Inc.	NC	26-2552129
USMD Diagnostic Services, LLC	TX	27-2803133
USMD of Arlington GP, L.L.C.	TX	73-1662757
Warner Family Practice, P.C.	AZ	86-0462952
WellMed Florida Medicare ACO, LLC	TX	84-2233329
WellMed Florida Services, PLLC	TX	45-2158334
WellMed Foundation Medicare ACO, LLC	TX	84-2193803
WellMed Medical Group, P.A.	TX	74-2574229
WellMed MSSP ACO, LLC	TX	84-2178104
WellMed Netw ork Medicare ACO, LLC	TX	84-2204650
WellMed Network of Florida, Inc.	TX	35-2314192
WellMed Networks, Inc.	TX	74-2889447
WellMed of Las Cruces, Inc.	TX	92-0183013
WellMed Texas Medicare ACO, LLC	TX	84-2219968
XLHome Michigan, P.C.	MI	46-3537245
XLHome Northeast, P.C.	NJ	45-5530241
XLHome Oklahoma, Inc.	OK	46-2931689
XLHome, P.C.	MD	27-3543997
Yorktow n ASO LLC	DE	99-1074356
Yorkville Endoscopy, LLC	NY	46-0857425

PART 1 - ORGANIZATIONAL CHART

Organizational Chart Footnotes

- (1) Entity is owned in full or in part by a UnitedHealth Group Incorporated friendly physician.
- (2) Control of the Foundation is based on sole membership, not the ownership of voting securities.
- (3) The remaining percentage is owned either by a non-affiliated entity, outside investor(s), current/former company officer(s), or third party shareholder(s).
- (4) The minority percentage is owned by one or more affiliated UnitedHealth Group Incorporated subsidiaries. Voting rights do vary.
- (5) No information of the other shareholder(s) has been provided
- (6) General partnership interests are held by United HealthCare Services, Inc. (89.77%) and by UnitedHealthcare, Inc. (10.23%). United HealthCare Services, Inc. also holds 100% of the limited partnership interests. When combining general and limited partner interests, United HealthCare Services, Inc. owns 94.18% and UnitedHealthcare, Inc. owns 5.83%.
- (7) Branch offices in Iraq and Uganda.
- (8) H&W Indemnity (SPC), Ltd. is an exempted segregated portfolio company organized under the laws of the Cayman Islands and holds a Cayman insurance license.
- (9) Registered as a foreign shareholder in Brazil.
- (10) Open
- (11) Polar II Fundo de Investimento em Participações is a Brazilian private equity investment fund incorporated in the form of a closed-end condominium.
- (12) N/A
- (13) Entity has a representative office in Beijing, China.
- (14) Open
- (15) Registered branch in the United Kingdom.
- (16) Open
- (17) Entity is not directly owned by the parent. However, the parent does have a viable economic interest as well as control over the entity through contractual agreements.

OVERFLOW PAGE FOR WRITE-INS

NONE